STIC-Biotech/ChemLib

RC261.A357

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

43/992

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

afc-RC261.A34

9460853

Searcher:_____
Phone:_____
Location:_____
Date Picked Up:_____
Date Completed:_____
Searcher Prep/Review:_____
Clerical:_____
Online time:_____

TYPE OF SEARCH:
NA Sequences:_____
AA Sequences:_____
Structures:_____
Bibliographic:_____
Litigation:_____
Full text:_____
Patent Family:_____
Other:_____

VENDOR/COST (where applic.)
STN:_____
DIALOG:_____
Questel/Orbit:_____
DRLink:_____
Lexis/Nexis:_____
Sequence Sys.:_____
WWW/Internet:_____
Other (specify):_____

STIC-Biotech/ChemLib OR180.L58 ~~BA 36.A1 E 57~~

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

Searcher:_____
Phone:_____
Location:_____
Date Picked Up:_____
Date Completed:_____
Searcher Prep/Review:_____
Clerical:_____
Online time:_____

TYPE OF SEARCH:
NA Sequences:_____
AA Sequences:_____
Structures:_____
Bibliographic:_____
Litigation:_____
Full text:_____
Patent Family:_____
Other:_____

VENDOR/COST (where applic.)
STN:_____
DIALOG:_____
Questel/Orbit:_____
DRLink:_____
Lexis/Nexis:_____
Sequence Sys.:_____
WWW/Internet:_____
Other (specify):_____

1: Eur J Immunol 1996 Dec;26(12):2924-32

CD66: role in the regulation of neutrophil effector function.

Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, Dransfield I.

Unit of Respiratory Medicine, University of Edinburgh Medical School, Scotland.

Neutrophils express several heavily glycosylated carcinoembryonic antigen (CEA)-related glycoproteins (CD66 antigens) which have been implicated in adhesion to E-selectin and as receptors for the lectins galectin 3 and bacterial type-1 fimbriae. The role of the CD66 antigens in neutrophil effector function was examined using non-cross-reacting and cross-reacting domain-mapped CD66 monoclonal antibody (mAb), which recognize epitopes on biliary glycoprotein (BGP; CD66a), CEA gene family member 6 (CGM6; CD66b), nonspecific cross-reacting antigen 90 (NCA90; CD66c) or CGM1 (CD66d). We show that BGP-specific mAb which recognize an AB-domain epitope strongly augment adhesion to fibrinogen by an Fc receptor- and beta2 integrin-dependent mechanism. Co-ligation of BGP with the glycophosphatidylinositol (GPI)-anchored CGM6 and NCA90 also caused increased beta2 integrin-mediated adhesion, receptor clustering and priming of formyl-Met-Leu-Phe (fMLP)-induced oxidant production by neutrophils, but only a small change in expression of L-selectin and CR3 compared to the chemotactic peptide fMLP. Ligation of CGM6 or NCA90 alone did not cause activation of the neutrophil in any of the assays used and did not cause priming of fMLP-induced oxidant production even when a secondary cross-linking reagent was used. We propose that specific cross-linking of neutrophil BGP with CGM6 and NCA90 contributes significantly to the regulation of neutrophil function during neutrophil recruitment.

PMID: 8977287 [PubMed - indexed for MEDLINE]

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  CA Section Thesaurus available in CAPLUS and CA
 NEWS 26  Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
 NEWS 27  Oct 21  EVENTLINE has been reloaded
 NEWS 28  Oct 24  BEILSTEIN adds new search fields
 NEWS 29  Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
 NEWS 30  Oct 25  MEDLINE SDI run of October 8, 2002
 NEWS 31  Nov 18  DKILIT has been renamed APOLLIT
 NEWS 32  Nov 25  More calculated properties added to REGISTRY
 NEWS 33  Dec 02  TIBKAT will be removed from STN
 NEWS 34  Dec 04  CSA files on STN
 NEWS 35  Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
 NEWS 36  Dec 17  TOXCENTER enhanced with additional content
 NEWS 37  Dec 17  Adis Clinical Trials Insight now available on STN
 NEWS 38  Dec 30  ISMEC no longer available
 NEWS 39  Jan 13  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 40  Jan 21  NUTRACEUT offering one free connect hour in February 2003
 NEWS 41  Jan 21  PHARMAML offering one free connect hour in February 2003
 NEWS 42  Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003

=> file medline, cancerlit, biosis, confsci, caplus, embase, uspatfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 14:14:19 ON 12 FEB 2003

FILE 'CANCERLIT' ENTERED AT 14:14:19 ON 12 FEB 2003

FILE 'BIOSIS' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CONFSCI' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 14:14:19 ON 12 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s granulocyte (a) antibody
L1         1723 GRANULOCYTE (A) ANTIBODY

=> s l1 and CML
L2           17 L1 AND CML

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3           14 DUP REM L2 (3 DUPLICATES REMOVED)

=> d 1-14

L3   ANSWER 1 OF 14  USPATFULL
AN     2003:4067  USPATFULL
TI     Interleukin-1 receptor antagonist-related molecules and uses thereof
IN     Saris, Christiaan M., Newbury Park, CA, UNITED STATES
       Giles, Jennifer, Newbury Park, CA, UNITED STATES
```

Mu, Sharon X., Thousand Oaks, CA, UNITED STATES
Xia, Min, Newbury Park, CA, UNITED STATES
Bass, Michael Brian, Thousand Oaks, CA, UNITED STATES
Craveiro, Roger, Thousand Oaks, CA, UNITED STATES
PA Amgen, Inc., A Corporation of the State of Delaware (U.S. corporation)
PI US 2003004106 A1 20030102
AI US 2002-139833 A1 20020506 (10)
RLI Division of Ser. No. US 2000-724583, filed on 28 Nov 2000, PENDING
PRAI US 1999-170191P 19991210 (60)
US 2000-188053P 20000309 (60)
US 2000-194521P 20000404 (60)
US 2000-195910P 20000410 (60)
DT Utility
FS APPLICATION
LN.CNT 5417
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 14 USPATFULL
AN 2002:300805 USPATFULL
TI Allogeneic and and xenogeneic transplantation
IN Sachs, David H., Newton, MA, UNITED STATES
PI US 2002168348 A1 20021114
AI US 2001-874512 A1 20010605 (9)
RLI Continuation of Ser. No. US 1998-126704, filed on 30 Jul 1998, ABANDONED Continuation of Ser. No. US 1995-458720, filed on 1 Jun 1995, GRANTED, Pat. No. US 5876708 Continuation-in-part of Ser. No. US 1994-266427, filed on 27 Jun 1994, GRANTED, Pat. No. US 5614187 Continuation-in-part of Ser. No. US 1995-451210, filed on 26 May 1995, GRANTED, Pat. No. US 6296846 Continuation of Ser. No. US 1992-838595, filed on 19 Feb 1992, ABANDONED Continuation of Ser. No. US 1994-220371, filed on 29 Mar 1994, ABANDONED Continuation of Ser. No. WO 1994-US5527, filed on 16 May 1994, UNKNOWN Continuation of Ser. No. US 1994-243653, filed on 16 May 1994, GRANTED, Pat. No. US 5658564 Continuation of Ser. No. US 1993-114072, filed on 30 Aug 1993, GRANTED, Pat. No. US 5624823 Continuation of Ser. No. US 1993-150739, filed on 10 Nov 1993, UNKNOWN Continuation of Ser. No. US 1994-212228, filed on 14 Mar 1994, UNKNOWN Continuation of Ser. No. WO 1994-US1616, filed on 14 Feb 1994, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 3241
INCL INCLM: 424/093.210
INCLS: 424/093.700; 514/009.000
NCL NCLM: 424/093.210
NCLS: 424/093.700; 514/009.000
IC [7]
ICM: A61K048-00
ICS: A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 14 USPATFULL
AN 2002:235523 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H., Newton, MA, UNITED STATES
PI US 2002127713 A1 20020912
AI US 2001-895713 A1 20010629 (9)
RLI Continuation of Ser. No. US 1997-910287, filed on 13 Aug 1997, GRANTED, Pat. No. US 6306651 Continuation of Ser. No. US 1996-759404, filed on 4 Dec 1996, ABANDONED Continuation of Ser. No. US 1994-266427, filed on 27 Jun 1994, GRANTED, Pat. No. US 5614187 Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, ABANDONED Continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1193
INCL INCLM: 435/325.000
INCLS: 424/093.210; 435/456.000
NCL NCLM: 435/325.000
NCLS: 424/093.210; 435/456.000
IC [7]
ICM: A61K048-00
ICS: C12N015-867
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 14 USPATFULL
AN 2002:85173 USPATFULL
TI IL-17 receptor like molecules and uses thereof
IN Jing, Shuqian, Thousand Oaks, CA, UNITED STATES
PI US 2002045213 A1 20020418
AI US 2001-809567 A1 20010315 (9)
RLI Continuation-in-part of Ser. No. US 2000-724460, filed on 28 Nov 2000, PENDING
PRAI US 2000-189816P 20000316 (60)
DT Utility
FS APPLICATION
LN.CNT 4685
INCL INCLM: 435/069.100
INCLS: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000
NCL NCLM: 435/069.100
NCLS: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000
IC [7]
ICM: A01K067-00
ICS: A61K048-00; C07H021-04; C12P021-02; C07K014-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 14 USPATFULL
AN 2002:66871 USPATFULL
TI IL-17 like molecules and uses thereof
IN Medlock, Eugene, Westlake Village, CA, UNITED STATES
Yeh, Richard, Princeton, NJ, UNITED STATES
Silbiger, Scott M., Woodland Hills, CA, UNITED STATES
Elliott, Gary S., Thousand Oaks, CA, UNITED STATES
Nguyen, Hung Q., Thousand Oaks, CA, UNITED STATES
Jing, Shuqian, Thousand Oaks, CA, UNITED STATES
PI US 2002037524 A1 20020328
AI US 2001-886404 A1 20010621 (9)
RLI Continuation-in-part of Ser. No. US 2001-810384, filed on 16 Mar 2001, PENDING
PRAI US 2001-266159P 20010202 (60)
US 2000-213125P 20000622 (60)
DT Utility
FS APPLICATION
LN.CNT 5737
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 14 USPATFULL
AN 2002:37315 USPATFULL

TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, LA, UNITED STATES
PI US 2002022031 A1 20020221
AI US 2001-924103 A1 20010808 (9)
PRAI US 2000-223698P 20000808 (60)
DT Utility
FS APPLICATION
LN.CNT 1133
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 14 USPATFULL
AN 2002:16578 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, UNITED STATES
Hershenson, Susan, Newbury Park, CA, UNITED STATES
Bevilacqua, Michael P., Boulder, CO, UNITED STATES
Collins, David S., Fishers, IN, UNITED STATES
PA Amgen Inc. (U.S. corporation)
PI US 2002009454 A1 20020124
AI US 2001-784623 A1 20010215 (9)
RLI Division of Ser. No. US 1998-131247, filed on 7 Aug 1998, PENDING
PRAI WO 1997-US2131 19970210
US 1997-55185P 19970808 (60)
DT Utility
FS APPLICATION
LN.CNT 3525
INCL INCLM: 424/178.100
NCL NCLM: 424/178.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 14 USPATFULL
AN 2001:185089 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6306651 B1 20011023
AI US 1997-910287 19970813 (8)
RLI Continuation of Ser. No. US 1996-759404, filed on 4 Dec 1996, now abandoned Continuation of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 5614187 Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned Continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, now abandoned
DT Utility
FS GRANTED
LN.CNT 1384
INCL INCLM: 435/325.000
INCLS: 435/366.000; 435/372.000; 424/093.200; 424/093.210
NCL NCLM: 435/325.000
NCLS: 424/093.200; 424/093.210; 435/366.000; 435/372.000
IC [7]
ICM: C12N015-85
ICS: A61K035-00
EXF 424/93.1; 424/93.21; 435/325; 435/366; 435/372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 14 USPATFULL
AN 2001:162845 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, United States
Hershenson, Susan, Newbury Park, CA, United States
Bevilacqua, Michael P., Boulder, CO, United States
Collins, David S., Fishers, IN, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6294170 B1 20010925
AI US 1998-131247 19980807 (9)
PRAI US 1997-55185P 19970808 (60)
DT Utility
FS GRANTED
LN.CNT 3022
INCL INCLM: 424/134.100
INCLS: 514/012.000; 530/324.000
NCL NCLM: 424/134.100
NCLS: 514/012.000; 530/324.000
IC [7]
ICM: A61K038-00
ICS: A61K039-395
EXF 424/134.1; 514/12; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 14 USPATFULL
AN 2000:98413 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Collins, David S., Lafayette, CO, United States
Bevilacqua, Michael P., Boulder, CO, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6096728 20000801
AI US 1997-798414 19970207 (8)
PRAI US 1996-11419P 19960209 (60)
US 1996-32789P 19961206 (60)
US 1997-36241P 19970123 (60)
US 1996-21443P 19960709 (60)
US 1996-36534P 19961206 (60)
US 1997-37737P 19970123 (60)
US 1997-39314P 19970207 (60)
DT Utility
FS Granted
LN.CNT 2432
INCL INCLM: 514/062.000
INCLS: 530/351.000
NCL NCLM: 514/062.000
NCLS: 530/351.000
IC [7]
ICM: A61K031-70
ICS: C07K001-00
EXF 514/62; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 14 USPATFULL
AN 1999:27177 USPATFULL
TI Allogeneic and xenogeneic transplantation
IN Sachs, David H., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5876708 19990302
AI US 1995-458720 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 5614187 And Ser. No. US 1995-451210, filed on 26 May 1995 which is a continuation of Ser. No. US 1995-838595, filed on 26 May 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-220371, filed on 29 Mar 1994, now abandoned Ser. No. Ser. No. US 1994-243653, filed on 16 May 1994, now patented, Pat. No. US 5685564 Ser. No. Ser. No. US 1993-114072, filed on 30 Aug 1993, now patented,

Pat. No. US 5624823 Ser. No. Ser. No. US 1993-150739, filed on 10 Nov 1993, now abandoned And Ser. No. US 1994-212228, filed on 14 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3535
INCL INCLM: 424/093.100
INCLS: 435/325.000
NCL NCLM: 424/093.100
NCLS: 435/325.000
IC [6]
ICM: A61K038-00
ICS: C12N005-08
EXF 424/93.1; 424/93.21; 435/32.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 14 USPATFULL
AN 97:24710 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5614187 19970325
AI US 1994-266427 19940627 (8)
RLI Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1304
INCL INCLM: 424/093.210
INCLS: 424/093.300; 424/577.000; 536/023.100; 536/023.500; 435/172.300
NCL NCLM: 424/093.210
NCLS: 424/093.300; 424/577.000; 435/456.000; 536/023.100; 536/023.500
IC [6]
ICM: C12N015-00
ICS: A01N063-00; A61K035-26; C07H021-04
EXF 424/93.21; 435/172.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 92073974 EMBASE
DN 1992073974
TI Determination of anti-neutrophil cytoplasm antibodies (ANCA) specificity by immunofluorescence on chronic myelocytic leukemia cells.
AU Chevailler A.; Noel L.H.; Renier G.; Gardembas-Pain M.; Subra J.F.; Nusbaum P.; Hurez D.; Lesavre P.
CS Laboratoire d'Immunopath., CHU,49040 Angers Cedex, France
SO Journal of Immunological Methods, (1992) 147/1 (101-109).
ISSN: 0022-1759 CODEN: JIMMBG
CY Netherlands
DT Journal; Article
FS 016 Cancer
025 Hematology
026 Immunology, Serology and Transplantation
LA English
SL English

L3 ANSWER 14 OF 14 MEDLINE DUPLICATE 1
AN 83135146 MEDLINE
DN 83135146 PubMed ID: 6962202
TI Monoclonal antibodies against human granulocytes and myeloid differentiation antigens.
AU Mannoni P; Janowska-Wieczorek A; Turner A R; McGann L; Turc J M
SO HUMAN IMMUNOLOGY, (1982 Dec) 5 (4) 309-23.
Journal code: 8010936. ISSN: 0198-8859.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198304
ED Entered STN: 19900318
Last Updated on STN: 19900318
Entered Medline: 19830407

=> d kwic 1-14

L3 ANSWER 1 OF 14 USPATFULL
DETD . . . tumor cells. Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (**CML** and AML) and other leukemias, multiple myeloma, lung cancer, breast cancer, tumor metastasis, and side effects from radiation therapy. Other. . .
DETD . . . following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF **antibodies**, **granulocyte** colony stimulating factor, thalidomide, BN 50730, tenidap, E 5531, tiapafant PCA 4248, nimesulide, panavir, rolipram, RP 73401, peptide T, MDL. . .

L3 ANSWER 2 OF 14 USPATFULL
DETD . . . Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAB MAR1 8.5; FITC-labelled rat-anti-mouse **granulocyte antibody** Gr1 is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased from Becton-Dickinson; FITC-labelled mouse-anti-human CD3 mAb Leu4 (Becton. . .
DETD . . . as confirmed by FCM. These chimeras recover normal cellular immune function 2-3 months after BMT, as tested by MLR and **CML** . Four such chimeric animals (see Table 1, numbers 1-4) received kidney transplants from donors class II matched to BMT donors. . . tubulointestinal infiltrate without signs of vascular injury. Both long-term survivors (pigs #3 & 5) were recently tested for anti-donor reactivity. **CML** and MLR revealed specific unresponsiveness to the kidney transplant donor type cells. Pigs #8-10 received kidney transplant from outbred Yorkshire. . .

L3 ANSWER 3 OF 14 USPATFULL
DETD [0091] Anti-class I Cell-Mediated Lympholysis (**CML**) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer, and a single. . .
DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAB MAR18.5; FITC-labelled rat-anti-mouse **granulocyte antibody** Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mAb is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased. . .

L3 ANSWER 4 OF 14 USPATFULL
DETD . . . Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (AML and **CML**) and other leukemias, multiple myeloma, lung, breast cancer, tumor metastasis, and side effects from radiation therapy. Other diseases involving tumor. . .
DETD . . . following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF **antibodies**, **granulocyte** colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . .

L3 ANSWER 5 OF 14 USPATFULL

DETD . . . Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (AML and **CML**) including myelomonocytic leukemis (M4 AML) and other leukemias, multiple myeloma, lung, breast cancer, tumor metastasis, and side effects from radiation. . .

DETD . . . following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs"), as defined herein), anti-TNF **antibodies**, **granulocyte** colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . .

DETD . . . useful in the diagnosis, treatment and prevention of lymphomas including non-hodgkin's lymphoma and Hodgkin's Disease; acute myelogenous leukemias (AML and **CML**) including premyelocytic leukemia (M3 AML), myelomonocytic leukemia (M4 AML), erythroleukemia (M6 AML) and megakaryocytic leukemia(M7 AML); acute lymphocytic leukemia including. . .

L3 ANSWER 6 OF 14 USPATFULL

AB Immunotherapy utilizing naked anti-**granulocyte antibodies** provides an effective means for treating chronic myelocytic leukemia (**CML**). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating **CML** is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating. . .

SUMM [0001] Chronic myelocytic leukemia (**CML**) is a highly specific disease that is defined by strict hematologic parameters that include a pathognomonic differential leukocyte count. Usually, **CML** is accompanied by the presence, in bone marrow cells, of the Ph chromosome, the first chromosomal anomaly to be regularly. . . phase when it behaves as a differentiated neoplasm and responds very well to simple, nonintensive therapy. After a variable interval, **CML** metamorphosizes to a refractory phase that responds poorly or not at all to therapy, even when intensive. See Spiers, Semin. Oncol., 22(4):380-95 (1995). At the stage of metamorphosis a great variety of clinical and hematologic pictures occur, and **CML** may mimic a myeloproliferative disease, a myelodysplasia, a subacute leukemia, acute myelocytic leukemia (AML), or acute lymphocytic leukemia (ALL). The. . . from the chronic phase to a so-called blastic crisis is incorrect. See Spiers, Semin. Oncol., 22(4):380-95 (1995). In most cases, **CML** is observed to undergo two or more stepwise evolutions, e.g., from chronic phase to an accelerated myeloproliferative phase to a. . .

SUMM [0002] A variety of therapies have been used to treat **CML**. Traditional methods for treating leukemia, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. The use of. . . duration of such treatments. Another therapy, allogeneic bone marrow transplants, has had the largest impact on survival among patients with **CML**. See Clarkson, J. Clin. Oncol., 3:135-139 (1985). Like the previous therapies, however, bone marrow transplants are poorly tolerated by patients.

SUMM [0005] There is a need, therefore, to develop immunotherapies which utilize naked antibodies to treat **CML**. Such therapies would cost-effectively treat patients without inducing toxic side-effects.

SUMM . . . objects, there is provided, in accordance with one aspect of the present invention, a method for treating chronic myelocytic leukemia (**CML**) in a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-**granulocyte antibody**. A variety of anti-**granulocyte antibodies** can be used in the present invention. Examples include, but are not limited to, anti-NCA-90, anti-NCA-95, MN-2, MN-15, NP-1 and NP2. In one embodiment, a single, naked anti-**granulocyte antibody** is administered to a patient while, in another, more than one anti-**granulocyte antibody** is administered. In still another embodiment, at least one naked anti-**granulocyte antibody** is administered to a patient in combination with naked antibodies directed to antigens present on a single granulocyte precursor, such. . .

SUMM [0008] In another embodiment of the present invention, naked anti-**granulocyte antibodies** are used in combination with other cancer therapies, e.g., an immunoconjugate or chemotherapy. Preferred immunoconjugates include radiolabeled antibody components and conjugates of an anti-**granulocyte antibody** component and an immunomodulator, such as a cytokine, stem cell growth factor, lymphotoxin or hematopoietic factor. In still another embodiment,. . .

SUMM [0009] In yet another embodiment of the present invention, naked anti-**granulocyte antibodies** are administered in combination with inducing agents which either enhance or induce the expression of the targeted antigen. Such inducing. . . surface of these cells. Accordingly, the antibodies of the present invention can be used to treat AML, as well as **CML**.

SUMM . . . a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-**granulocyte antibody** and an inducing agent, wherein the inducing agent induces expression of antigens which are minimally displayed on the surface of myeloblasts. As described above, the inventive method can be further combined with other naked, anti-**granulocyte antibodies**, antibody-toxin fusion proteins and other cancer therapies, e.g., an immunoconjugate or chemotherapy.

SUMM [0012] The present invention provides improved methods for treating myelocytic leukemia, particularly **CML**. The inventive methods utilize naked granulocyte-specific antibodies to destroy myeloid leukemia cells without the toxic side-effects normally associated with previous. . .

SUMM [0013] The anti-**granulocyte antibodies** used in the present invention are directed to antigens associated with various cell-types in the granulocyte lineage. Unlike in AML, malignant myeloblasts of **CML** patients differentiate into a variety of cell-types, including myelocytes, metamyelocytes, bands, and granulocytes. Accordingly, immunotherapy directed to one or two. . . inventive therapy recognize immature and mature granulocytes, the present invention provides an effective method for ridding malignant cells from a **CML** patient's bone marrow.

SUMM [0014] A variety of anti-**granulocyte antibodies** can be used in the present invention. In one embodiment, the inventive methods utilize anti-NCA-90 antibodies. A preferred example of. . .

SUMM [0020] The term "anti-**granulocyte antibody**" refers to an antibody which recognizes an antigen which is present on two or more cell-types of the granulocyte/myelocyte lineage.

SUMM [0057] The present invention contemplates the use of naked anti-**granulocyte antibodies** as the primary therapeutic composition of **CML**. However, in one embodiment of the invention, naked anti-**granulocyte antibodies**, e.g., MN-3 or MN-2, are administered to a patient in combination with one or more immunoconjugates. Such immunoconjugates can be. . .

SUMM [0077] Therapeutic Use of Anti-**Granulocyte Antibodies**

SUMM . . . granulocytes, the present invention provides an effective method for ridding malignant cells from a patient with myelocytic leukemia, in particular **CML**. As discussed above, a variety of anti-**granulocyte antibodies** can be used in the inventive therapy.

SUMM [0079] The present invention contemplates the use of naked anti-**granulocyte antibodies** as the primary therapeutic composition for treatment of **CML**. Such a composition can contain polyclonal anti-**granulocyte antibodies** or

monoclonal anti-**granulocyte antibodies**.

SUMM [0080] Methods for determining the binding specificity of an anti-**granulocyte antibody** are well-known to those of skill in the art. General methods are provided, for example, by Manson (ed.), METHODS IN. . .

SUMM [0081] In another embodiment of the present invention, naked anti-**granulocyte antibodies** can be used in combination with other cancer therapies, e.g., an immunoconjugate or chemotherapy. Such combination regimens are advantageous over. . . therapy. In such multimodal regimens, the supplemental therapeutic compositions can be administered before, concurrently, or after administration of the naked anti-**granulocyte antibodies**.

SUMM [0082] Preferred immunoconjugates include radiolabeled antibody components and conjugates of an anti-**granulocyte antibody** component and an immunomodulator. A radiolabeled immunoconjugate may comprise an .alpha.-emitting radioisotope, a .beta.-emitting radioisotope, a .gamma.-emitting radioisotope, an Auger. . .

SUMM [0089] In another embodiment, combination therapy utilizing naked, anti-**granulocyte antibodies** can comprise antibody-toxin fusion proteins. An antibody-toxin fusion protein is a fusion protein that comprises one or more antibody moieties. . .

SUMM [0092] Multimodal therapies of the present invention further include immunotherapy comprising two or more naked anti-**granulocyte antibodies**. In another embodiment, multimodal therapy comprises administration of naked anti-**granulocyte antibodies** supplemented with naked antibodies directed to antigens present on a single granulocyte precursor. For example, naked MN-3 antibodies can be. . .

SUMM . . . Tissue Antigens, 52:1-8 (1998). Accordingly, the antibodies of the present invention can be used to treat AML, as well as **CML** .

SUMM [0096] In another form of multimodal therapy, subjects receive naked anti-**granulocyte antibodies** and standard chemotherapy. Examples of chemotherapeutic agents include, but are not limited to, daunorubicin, cytarabine, 6-thioguanine, etoposide, mitoxantrone, diaziquone, idarubicin,. . .

SUMM [0097] In general, the dosage of administered naked anti-**granulocyte antibodies**, immunoconjugates, fusion proteins and additional therapeutics will vary depending upon such factors as the patient's age, weight, height, sex, general. . .

SUMM [0100] Preferably, naked anti-**granulocyte antibodies** are administered at low protein doses, such as 20 to 1500 milligrams protein per dose, given once, or repeatedly, parenterally. Alternatively, naked anti-**granulocyte antibodies** are administered in doses of 20 to 1000 milligrams protein per dose, or 20 to 500 milligrams protein per dose,. . .

SUMM [0101] As described above, the present invention also contemplates therapeutic methods in which naked anti-**granulocyte antibody** components are supplemented with immunoconjugate or fusion protein administration. In one variation, naked anti-**granulocyte antibodies** are administered with low-dose radiolabeled anti-**granulocyte antibodies** or fragments. As a second alternative, naked anti-**granulocyte antibodies** are administered with low-dose radiolabeled anti-granulocyte-cytokine immunoconjugates. As a third alternative, naked anti-**granulocyte antibodies** are administered with anti-granulocyte-cytokine immunoconjugates that are not radiolabeled. With regard to "low doses" of .sup.131I-labeled immunoconjugates, a preferable dosage. . .

SUMM [0103] The anti-**granulocyte antibodies**, immunoconjugates, and fusion proteins of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions,. . .

DETD [0109] 1. Method of Treating **CML** using Naked Anti-NCA-90 Antibody

DETD [0110] A patient with **CML** is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in. . .

DETD [0111] 2. Method of Treating **CML** using Combination Therapy Comprising Naked Anti-NCA-90 Antibody

DETD [0112] A patient with **CML** is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in. . .

CLM What is claimed:

1. A method for treating chronic myelocytic leukemia (**CML**) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-**granulocyte antibody**.

2. The method of claim 1, wherein said anti-**granulocyte antibody** is an anti-NCA-90 antibody.

4. The method of claim 1, wherein said anti-**granulocyte antibody** is an anti-NCA-95 antibody.

5. The method of claim 1, wherein said anti-**granulocyte antibody** is selected from the group consisting of MN-2, MN-15, NP-1 and NP-2.

. . . a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-**granulocyte antibody**, and an inducing agent, wherein said inducing agent induces expression of antigens which are minimally displayed on the surface of. . .

7. The method of claim 1, wherein said anti-**granulocyte antibody** is selected from the group consisting of subhuman primate antibody, murine monoclonal antobody, chimeric antibody, humanized antibody and human antibody.

. . .

18. The method of any of claim 1, wherein said therapeutic composition comprises two or more naked anti-**granulocyte antibodies**.

L3 ANSWER 7 OF 14 USPATFULL

SUMM . . . stroke, each of which may lead to neurodegeneration); lung diseases (e.g., ARDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and **CML**) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury;. . .

DETD . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and **CML**) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably. . .

DETD . . . the following TNF inhibitors: TNF binding proteins (soluble TNF receptor Type I and soluble TNF receptor Type II ("sTNFRs")), anti-TNF **antibodies**, **granulocyte** colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . .

DETD . . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and **CML**) and other leukemias.

L3 ANSWER 8 OF 14 USPATFULL

DETD Anti-class I Cell-Mediated Lympholysis (**CML**) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer, and a single. . .

DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be

stained by mouse anti-rat IgG-specific mAB MAR18.5; FITC-labelled rat-anti-mouse **granulocyte antibody** Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mAb is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased. . .

L3 ANSWER 9 OF 14 USPATFULL
SUMM . . . stroke, each of which may lead to neurodegeneration); lung diseases (e.g., ARDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and **CML**) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury;. . .
DETD . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and **CML**) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably. . .
DETD . . . the following TNF inhibitors: TNF binding proteins (soluble TNF receptor Type I and soluble TNF receptor Type II ("sTNFRs")), anti-TNF **antibodies**, **granulocyte** colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . .
DETD . . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and **CML**) and other leukemias.

L3 ANSWER 10 OF 14 USPATFULL
SUMM . . . stroke, each of which may lead to neurodegeneration); lung diseases (e.g., ARDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and **CML**) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury;. . .
DETD . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and **CML**) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably. . .
DETD . . . concurrent treatment) with any of one or more of the following TNF inhibitors: TNF binding proteins (soluble TNF receptors), anti-TNF **antibodies**, **granulocyte** colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T, MDL. . .
DETD . . . interferon (e.g., alpha interferon, beta interferon, gamma interferon or consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and **CML**) and other leukemias.

L3 ANSWER 11 OF 14 USPATFULL
DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAB MAR18.5; FITC-labelled rat-anti-mouse **granulocyte antibody** Gr1 is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased from Becton-Dickinson; FITC-labelled mouse-anti-human CD3 mAb Leu4 (Becton. . .
DETD . . . as confirmed by FCM. These chimeras recover normal cellular immune function 2-3 months after BMT, as tested by MLR and **CML** . Four such chimeric animals (see Table 1, numbers 1-4) received kidney transplants from donors class II matched to BMT donors. . . tubulointestinal infiltrate without signs of vascular injury. Both long-term survivors (pigs #3 & 5) were recently tested for anti-donor reactivity. **CML** and MLR revealed specific unresponsiveness to the kidney transplant donor type cells. Pigs #8-10 received kidney transplant from outbred Yorkshire. . .

L3 ANSWER 12 OF 14 USPATFULL
DETD Anti-class I Cell-Mediated Lympholysis (**CML**) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer, and a single. . .
DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAB MAR18.5; FITC-labelled rat-anti-mouse **granulocyte antibody** Gr1 is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mAb is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased. . .

L3 ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB . . . by the standard immunofluorescence method, derived from 37 patients with vasculitis were studied using formalin-acetone fixed chronic myelocytic leukemia cells (**CML**). All 37 sera were positive on **CML** cell smears. Furthermore formalin-acetone fixation selectively impaired antinuclear antibody binding without reducing ANCA staining and thus facilitated differentiation of these. . . is often difficult with the standard immunofluorescence method. Two unequivocal and mutually exclusive ANCA binding patterns were identified using the **CML** smears: (1) type I with diffuse granular binding confined to the polymorphonuclear (PMN) cell lineage and preferentially staining immature cells;. . .
CT Medical Descriptors:
*chronic myeloid leukemia
*vasculitis
*wegener granulomatosis
article
clinical article
controlled study
female
human
human cell
immunofluorescence
male
priority journal
***granulocyte antibody: EC, endogenous compound**
*myeloperoxidase: EC, endogenous compound

L3 ANSWER 14 OF 14 MEDLINE DUPLICATE 1
AB . . . mice with 99% pure granulocytes from normal donors or with a whole leukocyte suspension obtained from a chronic myelogenous leukemia (**CML**) patient, and then fusing the mouse spleen cells with a 315-43 myeloma cell clone. Four MCA were selected and studied using ELISA, immunofluorescence, cytotoxicity assays, and FACS analysis. Antibodies 80H.1, 80H.3, and 80H.5 (from normals) and 81H.1 (from **CML**) detected antigens expressed on neutrophils. Antibodies 80H.1 and 80H.3 (IgG) also reacted with monocytes but not with other blood cell. . . cytotoxic and reacted strongly with most of the cells of the neutrophil maturation sequence, i.e., myeloblasts, promyelocytes, myelocytes, and mature **granulocytes. Antibodies** 80H.5 and 81H.1 also inhibited CFU-GM growth stimulated by leukocyte feeder layers or placental conditioned media, but did not inhibit. . .

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)

=> s l1 and mn3
L4 22 L1 AND MN3

=> dup rem l4

PROCESSING COMPLETED FOR L4
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)

=> d 1-16

L5 ANSWER 1 OF 16 USPATFULL
AN 2002:99691 USPATFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton D., Mendham, NJ, UNITED STATES
PA IMMUNOMEDICS, INC. (U.S. corporation)
PI US 2002052594 A1 20020502
AI US 2001-2211 A1 20011205 (10)
RLI Division of Ser. No. US 1998-110181, filed on 6 Jul 1998, PATENTED
Division of Ser. No. US 1992-866789, filed on 7 Apr 1992, PATENTED
Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, PATENTED Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, PATENTED
DT Utility
FS APPLICATION
LN.CNT 1204
INCL INCLM: 604/522.000
INCLS: 604/020.000; 424/001.490
NCL NCLM: 604/522.000
NCLS: 604/020.000; 424/001.490
IC [7]
ICM: A61N001-30
ICS: A61B005-05; A61M031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:215819 CAPLUS
DN 137:348485
TI Imaging of low-grade bone infection with a technetium-99m labeled monoclonal anti-NCA-90 Fab' fragment in patients with previous joint surgery
AU Ivaneeviae, V.; Perka, C.; Hasart, O.; Sandrock, D.; Munz, D. L.
CS Humboldt University of Berlin, University Hospital Charite, Clinic for Nuclear Medicine, Berlin, 10117, Germany
SO European Journal of Nuclear Medicine and Molecular Imaging (2002), 29(4), 547-551
CODEN: EJNMA6
PB Springer-Verlag
DT Journal
LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 16 MEDLINE
AN 2002293701 MEDLINE
DN 21911989 PubMed ID: 11914895
TI Imaging of low-grade bone infection with a technetium-99m labelled monoclonal anti-NCA-90 Fab' fragment in patients with previous joint surgery.
CM Erratum in: Eur J Nucl Med Mol Imaging 2002 Jun;29(6):835
Erratum in: Ivaneeviae V [corrected to Ivancevic V]
AU Ivancevic V; Perka C; Hasart O; Sandrock D; Munz D L; Ivaneeviae V
CS Clinic for Nuclear Medicine, University Hospital Charite, Humboldt University of Berlin, Schumannstrasse 20-21, 10117 Berlin, Germany.. velimir.ivancevic@charite.de
SO Eur J Nucl Med Mol Imaging, (2002 Apr) 29 (4) 547-51.
Journal code: 101140988. ISSN: 1619-7070.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200210
ED Entered STN: 20020530
Last Updated on STN: 20030109
Entered Medline: 20021025

L5 ANSWER 4 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2002184867 EMBASE
TI Bone marrow scintigraphy with (99m)Tc labelled monoclonal anti-NCA 90 Fab' fragment: A feasibility study and comparison of bone marrow uptake with (99m)Tc labelled monoclonal anti-NCA 95 antigranulocyte antibody.
AU Ivancevic V.; Huic D.; Wolter A.; Munz D.L.
CS Dr. V. Ivancevic, Clinic for Nuclear Medicine, University Hospital Charite, Humboldt University, Schumannstr, 20-21, D-10117 Berlin, Germany. velimir.ivancevic@charite.de
SO Nuclear Medicine Communications, (2002) 23/3 (249-255).
Refs: 25
ISSN: 0143-3636 CODEN: NMCODC
CY United Kingdom
DT Journal; Article
FS 023 Nuclear Medicine
025 Hematology
037 Drug Literature Index
LA English
SL English

L5 ANSWER 5 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 2
AN 2003:35921 BIOSIS
DN PREV200300035921
TI Scintigraphic imaging of inflammatory processes.
AU Rennen, Huub J. J. M. (1); Boerman, Otto C.; Oyen, Wim J. G.; Corstens, Frans H. M.
CS (1) Department of Nuclear Medicine, University Medical Center Nijmegen, 6500 HB, P.O. Box 9101, Nijmegen, Netherlands: H.Rennen@nugen.azn.nl Netherlands
SO Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, (April 2002, 2002) Vol. 1, No. 1, pp. 63-75. print.
ISSN: 1568-0142.
DT General Review
LA English

L5 ANSWER 6 OF 16 USPATFULL
AN 2001:230931 USPATFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 6331175 B1 20011218
AI US 1998-110181 19980706 (9)
RLI Division of Ser. No. US 1992-866789, filed on 7 Apr 1992, now patented, Pat. No. US 5776093 Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210
DT Utility
FS GRANTED
LN.CNT 881
INCL INCLM: 604/522.000
INCLS: 604/020.000; 424/001.490
NCL NCLM: 604/522.000
NCLS: 424/001.490; 604/020.000
IC [7]
ICM: A61M025-00
EXF 600/436; 424/1.29; 424/1.45; 424/1.49; 424/9.34; 424/9.4; 424/9.71; 530/388.8; 530/388.85; 604/20; 604/21; 604/500; 604/522; 128/898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 16 MEDLINE DUPLICATE 3
AN 2001426446 MEDLINE
DN 21367183 PubMed ID: 11475075
TI Nonspecific bowel activity in imaging inflammation with Tc-99m labelled monoclonal anti-NCA-90 Fab' fragment **MN3**.
AU Ivancevic V; Wolter A; Munz D L
CS Klinik fur Nuklearmedizin, Universitatsklinikum Charite, Humboldt-Universitat zu Berlin.. velimir.ivancevic@charite.de
SO NUKLEARMEDIZIN, (2001 Jun) 40 (3) 71-4.
Journal code: 7609387. ISSN: 0029-5566.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200111
ED Entered STN: 20011105
Last Updated on STN: 20011105
Entered Medline: 20011101

L5 ANSWER 8 OF 16 MEDLINE
AN 1999378362 MEDLINE
DN 99378362 PubMed ID: 10451153
TI Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy.
AU Harwood S J; Valdivia S; Hung G L; Quenzer R W
CS Bay Pines Department of Veterans Affairs Medical Center, Florida 33744, USA.. harwood.steven_j@bay-pines.va.gov
SO CLINICAL INFECTIOUS DISEASES, (1999 Jun) 28 (6) 1200-5.
Journal code: 9203213. ISSN: 1058-4838.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199909
ED Entered STN: 19990925
Last Updated on STN: 19990925
Entered Medline: 19990915

L5 ANSWER 9 OF 16 MEDLINE DUPLICATE 4
AN 1999105506 MEDLINE
DN 99105506 PubMed ID: 9890500
TI Immunoscintigraphy of an inflammatory process in Crohn's disease with a technetium-99m-labeled fragment (**MN3** Fab') and with an intact monoclonal anti-**granulocyte antibody** (Mab BW 250/183).
AU Kresnik E; Gallowitsch H J; Mikosch P; Molnar M; Unterweger O; Gomez I; Lind P
CS Department of Nuclear Medicine and Endocrinology, Landeskrankenhaus Klagenfurt, Austria.. Abteilung@lkh-klu.at
SO CLINICAL NUCLEAR MEDICINE, (1999 Jan) 24 (1) 64-5.
Journal code: 7611109. ISSN: 0363-9762.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199903
ED Entered STN: 19990326
Last Updated on STN: 19990326
Entered Medline: 19990316

L5 ANSWER 10 OF 16 USPATFULL
AN 1998:78371 USPATFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5776095 19980707
AI US 1995-456914 19950601 (8)
RLI Division of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210
DT Utility
FS Granted
LN.CNT 891
INCL INCLM: 604/020.000
INCLS: 424/001.410; 424/001.490
NCL NCLM: 604/020.000
NCLS: 424/001.410; 424/001.490
IC [6]
ICM: A61N001-30
ICS: A61K051-00
EXF 604/28; 604/49; 604/20; 128/898; 424/178.1; 424/1.41; 424/1.49; 424/9.34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 16 USPATFULL
AN 1998:78370 USPATFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5776094 19980707
AI US 1995-456629 19950601 (8)
RLI Continuation of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210
DT Utility
FS Granted
LN.CNT 963
INCL INCLM: 604/020.000
INCLS: 600/420.000; 530/388.200; 530/391.300; 424/001.490
NCL NCLM: 604/020.000
NCLS: 424/001.490; 530/388.200; 530/391.300; 600/420.000
IC [6]
ICM: A61H001-30
ICS: A61K035-14
EXF 128/653.1; 128/653.2; 128/653.4; 128/654; 604/20; 604/28; 604/49; 424/1.49; 530/389.8; 530/391.3; 530/388.2; 600/410; 600/411; 600/420

L5 ANSWER 12 OF 16 USPATFULL
AN 1998:78369 USPATFULL
TI Method for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5776093 19980707
AI US 1992-866789 19920407 (7)
RLI Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210, issued on 5 Apr 1988
DT Utility
FS Granted
LN.CNT 875
INCL INCLM: 604/020.000
INCLS: 600/420.000; 530/388.200; 530/391.300; 424/001.490
NCL NCLM: 604/020.000
NCLS: 424/001.490; 530/388.200; 530/391.300; 600/420.000
IC [6]
ICM: A61N001-30
ICS: A61K035-14
EXF 128/653.1; 128/653.2; 128/653.4; 128/654; 436/806; 424/4; 424/7;

424/1.1; 424/1.49; 358/111; 324/307; 324/310; 604/20; 604/28; 604/49; 530/388.2; 530/389.8; 530/391.3; 600/410; 600/411; 600/420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 16 USPATFULL
AN 97:117409 USPATFULL
TI Method for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5697902 19971216
AI US 1995-456909 19950601 (8)
RLI Continuation of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210
DT Utility
FS Granted
LN.CNT 913
INCL INCLM: 604/049.000
INCLS: 604/021.000; 128/898.000
NCL NCLM: 604/500.000
NCLS: 128/898.000; 604/021.000
IC [6]
ICM: A61M031-00
EXF 128/898; 604/28; 604/49; 604/21

L5 ANSWER 14 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 96341152 EMBASE
DN 1996341152
TI Intussusception secondary to Meckel's diverticulum: Detection with Tc- 99m monoclonal antibodies to granulocytes (LeukoScan.RTM.).
AU Barron B.J.; Robins D.B.; Lamki L.M.; Daniels W.; Chopra L.; Black C.T.
CS Department of Radiology, University of Texas Medical School, 6431 Fannin,Houston, TX 77030, United States
SO Clinical Nuclear Medicine, (1996) 21/11 (834-837).
ISSN: 0363-9762 CODEN: CNMEDK
CY United States
DT Journal; Article
FS 007 Pediatrics and Pediatric Surgery
023 Nuclear Medicine
037 Drug Literature Index
048 Gastroenterology
LA English
SL English

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1996:144036 BIOSIS
DN PREV199698716171
TI Comparative pharmacokinetics, dosimetry, and in-vivo stability of two formulations of 99mTc-labeled anti-**granulocyte antibody** fab' fragment (IMMU-**MN3**, LeukoScan TM.
AU Webster, William B.; Harwood, Steven H.; Carroll, Robert G.; Morrissey, Michele; Hakki, Sam
CS Bay Pines VA Med. Cent., Bay Pines, FL USA
SO Pharmacotherapy, (1996) Vol. 16, No. 1, pp. 131-132.
Meeting Info.: American College of Clinical Pharmacy 1996 Winter Practice and Research Forum Monterey, California, USA February 11-14, 1996
ISSN: 0277-0008.
DT Conference
LA English

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1995:525470 BIOSIS
DN PREV199598539770
TI The diagnostic and clinical utility of 99mTc-labeled anti-**granulocyte antibody** IMMU-**MN3** scan (Leukoscan) in osteomyelitis compared to WBC scans.
AU Quenzer, R. W. (1); Danska, Jeff; (usa), The Immunomedics Oseomyelitis Clinical Study Group
CS (1) Univ. New Mexico, Albuquerque, NM USA
SO Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (1995) Vol. 35, No. 0, pp. 77.
Meeting Info.: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, California, USA September 17-20, 1995
DT Conference
LA English

```
=> d ab 16

L5   ANSWER 16 OF 16  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.


=> d ab 15

L5   ANSWER 15 OF 16  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.


=> d 9 ab

L5   ANSWER 9 OF 16     MEDLINE                          DUPLICATE 4


=> d his

     (FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

     FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
     ENTERED AT 14:14:19 ON 12 FEB 2003
L1          1723 S GRANULOCYTE (A) ANTIBODY
L2            17 S L1 AND CML
L3            14 DUP REM L2 (3 DUPLICATES REMOVED)
L4            22 S L1 AND MN3
L5            16 DUP REM L4 (6 DUPLICATES REMOVED)

=> s l1 and administrat?
L6          293 L1 AND ADMINISTRAT?

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           282 DUP REM L6 (11 DUPLICATES REMOVED)

=> s l7 not yp=>2000
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
L8          282 L7 NOT YP=>2000

=> s l7 not py=>2000
'2000' NOT A VALID FIELD CODE
L9          234 L7 NOT PY=>2000

=> s l9 and nca (a) 90
L10           2 L9 AND NCA (A) 90

=> d 1-2
```

L10 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2000038864 EMBASE
TI [Immunoscintigraphy with 99mTc-labelled antigranulocyte monovalent antibody fragments: Diagnostic features in a case of brain abscess]. IMMUNOSCINTIGRAFIA CON FRAMMENTI ANTICORPALI MONOVALENTI ANTI- GRANULOCITI MARCATI CON 99^MTC: ASPETTI DIAGNOSTICI IN UN CASO DI ASCESSO CEREBRALE.
AU Dimonte M.; Di Pierro G.
CS Dr. M. Dimonte, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy
SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).
Refs: 16
ISSN: 1120-9976 CODEN: RIVNEJ
CY Italy
DT Journal; Article
FS 008 Neurology and Neurosurgery
014 Radiology
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA Italian
SL English; Italian

L10 ANSWER 2 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 94276417 EMBASE
DN 1994276417
TI Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment.
AU Becker W.; Bair J.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki M.; Winship M.J.; Goldenberg D.M.; Wolf F.
CS Dept. of Nuclear Medicine, University of Erlangen-Nuremberg, Krankenhausstrasse 12,D-91054 Erlangen, Germany
SO Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).
ISSN: 0161-5505 CODEN: JNMEAQ
CY United States
DT Journal; Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90

=> s l9 and nca
L11 10 L9 AND NCA

=> d 1-10

L11 ANSWER 1 OF 10 MEDLINE
AN 93235524 MEDLINE
DN 93235524 PubMed ID: 8475680
TI [Immunoscintigraphy for detection of inflammatory perioperative foci]. Immunszintigraphie zur Aufdeckung entzundlicher perioperativer Foci.
AU Kroiss A; Sporn P; Auinger C; Redl E; Bock F; Dinstl K; Neumayr A
CS Institut fur Nuklearmedizin, Krankenanstalt Rudolfstiftung, Wien.
SO ACTA MEDICA AUSTRIACA, (1993) 20 (1-2) 45-9.
Journal code: 7501997. ISSN: 0303-8173.
CY Austria
DT Journal; Article; (JOURNAL ARTICLE)
LA German
FS Priority Journals
EM 199305
ED Entered STN: 19930604
Last Updated on STN: 19970203
Entered Medline: 19930520

L11 ANSWER 2 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2000038864 EMBASE
TI [Immunoscintigraphy with 99mTc-labelled antigranulocyte monovalent antibody fragments: Diagnostic features in a case of brain abscess]. IMMUNOSCINTIGRAFIA CON FRAMMENTI ANTICORPALI MONOVALENTI ANTI- GRANULOCITI MARCATI CON 99^MTC: ASPETTI DIAGNOSTICI IN UN CASO DI ASCESSO CEREBRALE.
AU Dimonte M.; Di Pierro G.
CS Dr. M. Dimonte, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy
SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).
Refs: 16
ISSN: 1120-9976 CODEN: RIVNEJ
CY Italy
DT Journal; Article
FS 008 Neurology and Neurosurgery
014 Radiology
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA Italian
SL English; Italian

L11 ANSWER 3 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1999147732 EMBASE
TI Photopenic lesions in bone marrow scintigraphy using technetium-99m labeled antigranulocyte antibody without known turnout.
AU Krause Th.; Reinhardt M.; Nitzsche E.; Moser E.
CS Th. Krause, Radiologische Klinik, Abteilung Nuklearmedizin, Hugstetter Strasse 55, D-79106 Freiburg, Germany. krauseth@ukl.uni-freiburg.de
SO NuklearMedizin, (1999) 38/3 (85-89).
Refs: 24
ISSN: 0029-5566 CODEN: NUMEEL
CY Germany
DT Journal; Article
FS 016 Cancer
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English; German

L11 ANSWER 4 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1998176729 EMBASE
TI 99Tc(m)-labelled chimeric human/mouse antigranulocyte antibody bone marrow scintigraphy: A preliminary clinical study.
AU Higuchi T.; Inoue T.; Sarwar M.; Oriuchi N.; Karasawa M.; Naruse T.;

Yamanaka H.; Watanabe T.; Chung J.-K.; Endo K.
CS K. Endo, Departments of Nuclear Medicine, Gunma University School of Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371, Japan
SO Nuclear Medicine Communications, (1998) 19/5 (463-474).
Refs: 22
ISSN: 0143-3636 CODEN: NMCODC
CY United Kingdom
DT Journal; Article
FS 014 Radiology
016 Cancer
023 Nuclear Medicine
025 Hematology
037 Drug Literature Index
LA English
SL English

L11 ANSWER 5 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 94276417 EMBASE
DN 1994276417
TI Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment.
AU Becker W.; Bair J.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki M.; Winship M.J.; Goldenberg D.M.; Wolf F.
CS Dept. of Nuclear Medicine, University of Erlangen-Nuremberg, Krankenhausstrasse 12,D-91054 Erlangen, Germany
SO Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).
ISSN: 0161-5505 CODEN: JNMEAQ
CY United States
DT Journal; Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

L11 ANSWER 6 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 93043073 EMBASE
DN 1993043073
TI 111Indium-F(ab)'2-**NCA** 102 monoclonal antibody: In vitro study of a specific agent for the detection of inflammatory foci.
AU Collet B.; Maros S.; Moisan A.; Le Cloirec J.; Moinereau M.; Aumaitre E.; Toujas L.; Bourguet P.
CS Serv. Immunologie/Medicine Nucleaire, CRLCC Eugene Marquis, Rue de la Bataille Flandre-Dunkerque,35062 Rennes Cedex, France
SO Nuclear Medicine and Biology, (1993) 20/2 (175-182).
ISSN: 0883-2897 CODEN: NMBIEO
CY United Kingdom
DT Journal; Article
FS 009 Surgery
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

L11 ANSWER 7 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 92086939 EMBASE
DN 1992086939
TI The single late 99Tcm **granulocyte antibody** scan in inflammatory diseases.
AU Becker W.S.; Saptogino A.; Wolf F.G.
CS Department of Nuclear Medicine of the Friedrich-Alexander University of Erlangen-Nurnberg, Krankenhausstrasse 12, 8520 Erlangen, Germany
SO Nuclear Medicine Communications, (1992) 13/3 (186-192).
ISSN: 0143-3636 CODEN: NMCODC
CY United Kingdom
DT Journal; Conference Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA English
SL English

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 89000602 EMBASE
DN 1989000602
TI In vivo labelling of granulocytes using 123I-tagged anti-**granulocyte antibodies**.
AU Seybold K.
CS Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland
SO Nuclear Medicine Communications, (1988) 9/10 (745-752).
ISSN: 0143-3636 CODEN: NMCODC
CY United Kingdom
DT Journal
FS 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index
LA English
SL English

L11 ANSWER 9 OF 10 USPATFULL
AN 97:44738 USPATFULL
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5632968 19970527
AI US 1994-338100 19941109 (8)
RLI Continuation of Ser. No. US 1991-694977, filed on 6 May 1991, now patented, Pat. No. US 5364612
DT Utility
FS Granted
LN.CNT 1053
INCL INCLM: 424/001.490
INCLS: 424/009.340
NCL NCLM: 424/001.490
NCLS: 424/009.340
IC [6]
ICM: A61K051-10
ICS: A61B005-055
EXF 424/1.49; 424/1.53; 424/9.34; 424/179.1; 424/180.1; 424/182.1

L11 ANSWER 10 OF 10 USPATFULL
AN 94:99668 USPATFULL
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States
PA Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
PI US 5364612 19941115
AI US 1991-694977 19910506 (7)
DT Utility
FS Granted
LN.CNT 1163
INCL INCLM: 424/001.530
INCLS: 424/001.490; 424/009.000; 424/136.100; 424/152.100; 424/153.100; 424/154.100; 424/172.100; 424/173.100; 530/391.300
NCL NCLM: 424/001.530
NCLS: 424/001.490; 424/009.341; 424/136.100; 424/152.100; 424/153.100;

424/154.100; 424/172.100; 424/173.100; 530/391.300
IC [5]
ICM: A61K049-02
ICS: A61K039-395
EXF 424/1.1; 424/9; 424/1.49; 424/1.53; 530/396; 530/402; 530/409; 530/388.25; 530/388.7; 530/391.1; 530/391.3

=> d 8 ab

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; **NCA** 95) of normal human granulocytes. This new tracer was quality tested and radioiodinated with 123I (123I Mab 47) for clinical use according to established procedures. Extended in vitro studies revealed a high selectivity for granulocytes without inhibiting their vital functions. In vivo cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of 123I. Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of 123I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of 111In-labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.

=> d ibib ab 8

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 89000602 EMBASE
DOCUMENT NUMBER: 1989000602
TITLE: In vivo labelling of granulocytes using 123I-tagged anti-**granulocyte antibodies**.
AUTHOR: Seybold K.
CORPORATE SOURCE: Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland
SOURCE: Nuclear Medicine Communications, (1988) 9/10 (745-752). ISSN: 0143-3636 CODEN: NMCODC
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT: 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; **NCA** 95) of normal human granulocytes. This new tracer was quality tested and radioiodinated with 123I (123I Mab 47) for clinical use according to established procedures. Extended in vitro studies revealed a high selectivity for granulocytes without inhibiting their vital functions. In vivo cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of 123I. Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of 123I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of 111In-labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA

=> s cml
L12 32001 CML

=> s l12 and granulocyte
L13 3824 L12 AND GRANULOCYTE

=> s l13 and antibod?
L14 831 L13 AND ANTIBOD?

=> s l14 and nca?
L15 23 L14 AND NCA?

=> dup rem l15
PROCESSING COMPLETED FOR L15
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)

=> d.1-18

L16 ANSWER 1 OF 18 USPATFULL
AN 2003:23733 USPATFULL
TI Polymerase kappa compositions and methods thereof
IN Friedberg, Errol C., Dallas, TX, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Feaver, William J., Branford, CT, UNITED STATES
PA Board of Regents, The University of Texas system (U.S. corporation)
PI US 2003017573 A1 20030123
AI US 2001-971101 A1 20011004 (9)
PRAI US 2000-238289P 20001004 (60)
DT Utility
FS APPLICATION
LN.CNT 7042
INCL INCLM: 435/226.000

INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06

L16 ANSWER 2 OF 18 USPATFULL
AN 2003:17897 USPATFULL
TI Nucleic acids, proteins, and **antibodies**
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2003013649 A1 20030116
AI US 2001-989442 A1 20011121 (9)
RLI Continuation of Ser. No. US 2001-764863, filed on 17 Jan 2001, ABANDONED
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001020 (60)
US 2000-246475P 20001108 (60)
US 2000-231243P 20000908 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-234998P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001108 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001117 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)

US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
DT Utility
FS APPLICATION
LN.CNT 27547
INCL INCLM: 514/012.000
INCLS: 536/023.500; 530/350.000; 435/006.000; 435/325.000; 435/069.100; 435/320.100
NCL NCLM: 514/012.000
NCLS: 536/023.500; 530/350.000; 435/006.000; 435/325.000; 435/069.100; 435/320.100
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C12P021-02; C12N005-06; C12Q001-68; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 18 USPATFULL
AN 2003:10679 USPATFULL
TI Methods and compositions relating to improved lentiviral vectors and their applications
IN Trono, Didier, Collonge, SWITZERLAND
Salmon, Patrick, Arenthon, FRANCE
PA Research Development Foundation (non-U.S. corporation)
PI US 2003008374 A1 20030109
AI US 2001-10081 A1 20011109 (10)
PRAI US 2000-248398P 20001113 (60)
DT Utility
FS APPLICATION
LN.CNT 2923
INCL INCLM: 435/235.100
INCLS: 435/456.000; 435/320.100
NCL NCLM: 435/235.100
NCLS: 435/456.000; 435/320.100
IC [7]
ICM: C12N015-867
ICS: C12N007-01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 18 USPATFULL
AN 2002:329426 USPATFULL
TI Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
IN Zou, Yiyu, Bronx, NY, UNITED STATES
Perez-Soler, Roman, New York, NY, UNITED STATES
PI US 2002187105 A1 20021212
AI US 2002-61444 A1 20020201 (10)
PRAI US 2001-266174P 20010201 (60)
DT Utility
FS APPLICATION
LN.CNT 5666
INCL INCLM: 424/045.000
INCLS: 424/078.380; 514/002.000
NCL NCLM: 424/045.000
NCLS: 424/078.380; 514/002.000
IC [7]
ICM: A61K031-785
ICS: A61K038-16; A61L009-04; A61K031-77
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 18 USPATFULL
AN 2002:315069 USPATFULL
TI Compositions and methods for treatment of neoplastic disease
IN Terman, David S., Pebble Beach, CA, UNITED STATES
PI US 2002177551 A1 20021128
AI US 2001-870759 A1 20010530 (9)
PRAI US 2000-208128P 20000531 (60)
DT Utility
FS APPLICATION
LN.CNT 17323
INCL INCLM: 514/012.000
INCLS: 435/325.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 435/325.000; 530/350.000
IC [7]
ICM: A61K038-17
ICS: C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 18 USPATFULL
AN 2002:280013 USPATFULL
TI Gene differentially expressed in breast cancer, and encoded polypeptides
IN Zauderer, Maurice, Pittsford, NY, UNITED STATES
Evans, Elizabeth E., Rochester, NY, UNITED STATES
Borrello, Melinda A., Pittsford, NY, UNITED STATES
PI US 2002155447 A1 20021024
AI US 2001-824787 A1 20010404 (9)
PRAI US 2000-194463P 20000404 (60)
DT Utility
FS APPLICATION
LN.CNT 8851
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 18 USPATFULL
AN 2002:272939 USPATFULL
TI PEI: DNA vector formulations for in vitro and in vivo gene delivery
IN Cristiano, Richard J., Pearland, TX, UNITED STATES
Yamashita, Motoyuki, Kochi City, JAPAN
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002151060 A1 20021017
AI US 2001-962922 A1 20010925 (9)
PRAI US 2000-235237P 20000925 (60)

US 2000-235635P 20000926 (60)
DT Utility
FS APPLICATION
LN.CNT 7002
INCL INCLM: 435/455.000
INCLS: 514/044.000; 424/486.000
NCL NCLM: 435/455.000
NCLS: 514/044.000; 424/486.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87; A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 18 USPATFULL
AN 2002:251760 USPATFULL
TI 55054, a novel human metalloprotease and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139 (U.S. corporation)
PI US 2002137713 A1 20020926
AI US 2001-963290 A1 20010925 (9)
PRAI US 2000-235055P 20000925 (60)
DT Utility
FS APPLICATION
LN.CNT 4034
INCL INCLM: 514/044.000
INCLS: 435/455.000; 536/023.200
NCL NCLM: 514/044.000
NCLS: 435/455.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 18 USPATFULL
AN 2002:191201 USPATFULL
TI Uses of monoclonal **antibody** 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002102264 A1 20020801
AI US 2001-982645 A1 20011018 (9)
PRAI US 2000-241344P 20001018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
INCLS: 424/178.100; 530/389.100; 435/326.000
NCL NCLM: 424/155.100
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]
ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 18 USPATFULL
AN 2002:165193 USPATFULL
TI Nucleic acids, proteins, and **antibodies**
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086822 A1 20020704
AI US 2001-764886 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
DT Utility
FS APPLICATION
LN.CNT 20931
INCL INCLM: 514/012.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100
NCL NCLM: 514/012.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 18 USPATFULL
AN 2002:165192 USPATFULL
TI Nucleic acids, proteins, and **antibodies**
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086821 A1 20020704

AI US 2001-764881 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
DT Utility
FS APPLICATION
LN.CNT 27531
INCL INCLM: 514/012.000
INCLS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 18 USPATFULL
AN 2002:164712 USPATFULL
TI Nucleic acids, proteins, and **antibodies**
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002086330 A1 20020704
AI US 2001-764893 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
DT Utility
FS APPLICATION
LN.CNT 25862
INCL INCLM: 435/007.100
INCLS: 536/023.100
NCL NCLM: 435/007.100
NCLS: 536/023.100
IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 18 USPATFULL
AN 2002:126343 USPATFULL
TI Genes that regulate hematopoietic blood forming stem cells and uses thereof
IN Lemischka, Ihor, Princeton, NJ, UNITED STATES
Moore, Kateri, Princeton, NJ, UNITED STATES
PI US 2002064855 A1 20020530
AI US 2001-789919 A1 20010221 (9)
PRAI WO 1999-US19052 19990820
DT Utility
FS APPLICATION
LN.CNT 6639
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/189.000
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/189.000
IC [7]
ICM: C12N009-02
ICS: C12N009-64; C07H021-04; C12P021-02; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 18 USPATFULL
AN 2002:37315 USPATFULL
TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, LA, UNITED STATES
PI US 2002022031 A1 20020221
AI US 2001-924103 A1 20010808 (9)
PRAI US 2000-223698P 20000808 (60)
DT Utility
FS APPLICATION
LN.CNT 1133
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 18 USPATFULL
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

PI US 6495129 B1 20021217
AI US 2000-689693 20001013 (9)
RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719, filed on 30 Sep 1996, now patented, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part of Ser. No. US 208339
PRAI US 2000-212658P 20000619 (60)
US 2000-211458P 20000613 (60)
US 2000-199142P 20000424 (60)
US 2000-189048P 20000314 (60)
US 1999-172063P 19991223 (60)
US 1999-164059P 19991108 (60)
US 1999-159362P 19991014 (60)
DT Utility
FS GRANTED
LN.CNT 14198
INCL INCLM: 424/085.100
INCLS: 424/885.000; 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 424/085.100
NCLS: 514/002.000; 514/008.000; 514/012.000
IC [7]
ICM: A61K038-19
EXF 424/85.1; 424/885; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 18 USPATFULL
AN 2001:231143 USPATFULL
TI Arrays for identifying agents which mimic or inhibit the activity of interferons
IN Silverman, Robert H., Beachwood, OH, United States
Williams, Bryan R. G., Cleveland, OH, United States
Der, Sandy, Cleveland, OH, United States
PA The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S. corporation)
PI US 6331396 B1 20011218
AI US 1999-405438 19990923 (9)
PRAI US 1998-101497P 19980923 (60)
DT Utility
FS GRANTED
LN.CNT 9639
INCL INCLM: 435/006.000
INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
NCL NCLM: 435/006.000
NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
IC [7]
ICM: C12Q001-68
ICS: C12M001-36; C07H021-04
EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 18 MEDLINE DUPLICATE 1
AN 91187141 MEDLINE
DN 91187141 PubMed ID: 2011210
TI Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
AU Noworolska A; Slesak B; Harlonzinska A; Richter R
CS Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
SO NEOPLASMA, (1991) 38 (1) 57-62.
Journal code: 0377266. ISSN: 0028-2685.
CY Czech Republic
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199105
ED Entered STN: 19910526
Last Updated on STN: 19960719
Entered Medline: 19910503

L16 ANSWER 18 OF 18 MEDLINE DUPLICATE 2
AN 82141196 MEDLINE
DN 82141196 PubMed ID: 6949877
TI Clinical evaluation of **NCA** in patients with chronic myelocytic leukemia.
AU Wahren B; Gahrton G; Ruden U; Hammarstrom S
SO INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7.
Journal code: 0042124. ISSN: 0020-7136.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198205
ED Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820512

=> d 17 18 ibib ab

L16 ANSWER 17 OF 18 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 91187141 MEDLINE
DOCUMENT NUMBER: 91187141 PubMed ID: 2011210
TITLE: Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
AUTHOR: Noworolska A; Slesak B; Harlonzinska A; Richter R
CORPORATE SOURCE: Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
SOURCE: NEOPLASMA, (1991) 38 (1) 57-62.
Journal code: 0377266. ISSN: 0028-2685.
PUB. COUNTRY: Czech Republic
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 19910526
Last Updated on STN: 19960719
Entered Medline: 19910503
AB The distribution of peanut agglutinin (PNA) receptors, nonspecific cross-reacting antigen (**NCA**) molecule and 3-fucosyl-N-acetyllactosamine (FAL) in myeloid leukemic cells isolated by density gradient centrifugation was compared using immunofluorescence test (IF). Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low percentage of **NCA**+ and PNA+ cells. In chronic and acute phase of chronic myelocytic leukemias (**CML**) the number of **NCA** containing cells increased and the amount of PNA-binding cells decreased as more mature granulocytic fractions were isolated on Ficoll--Uropoline density gradient. In patients with myeloblastic crisis of **CML** (**CML**-BC) the number of cells expressing FAL structure did not change in relation to maturation stage of myeloid cells. Our results

revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature **granulocytes**.

L16 ANSWER 18 OF 18 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 82141196 MEDLINE
DOCUMENT NUMBER: 82141196 PubMed ID: 6949877
TITLE: Clinical evaluation of **NCA** in patients with chronic myelocytic leukemia.
AUTHOR: Wahren B; Gahrton G; Ruden U; Hammarstrom S
SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7.
Journal code: 0042124. ISSN: 0020-7136.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198205
ENTRY DATE: Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820512

AB **NCA**, a normal colon and **granulocyte** antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil **granulocytes**, was studied in 50 **CML** patients in various stages of the disease. Radioimmunoassay was used to demonstrate **NCA** in serum. Untreated **CML** patients had a mean level of 732 micrograms **NCA**/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms **NCA**/l. The serum **NCA** levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of **CML**. In blast crisis low values with a mean of 109 micrograms **NCA**/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of **NCA** could not be attributed to **antibodies** to **NCA**.
NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of **NCA** by leukemic maturing myeloid cells.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA
L12 32001 S CML
L13 3824 S L12 AND GRANULOCYTE
L14 831 S L13 AND ANTIBOD?
L15 23 S L14 AND NCA?
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)

=> s l14 and humaniz?
L17 204 L14 AND HUMANIZ?

=> s l17 and cd33
L18 24 L17 AND CD33

=> dup rem l18
PROCESSING COMPLETED FOR L18
L19 24 DUP REM L18 (0 DUPLICATES REMOVED)

=> d 1-24

L19 ANSWER 1 OF 24 USPATFULL
AN 2003:38351 USPATFULL
TI Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
IN Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
Barnes, Thomas M., Brookline, MA, UNITED STATES
PI US 2003027998 A1 20030206
AI US 2001-796753 A1 20010301 (9)
RLI Continuation-in-part of Ser. No. US 1998-183175, filed on 30 Oct 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-599596, filed on 22 Jun 2000, ABANDONED Division of Ser. No. US 1998-223546, filed on 30 Dec 1998, ABANDONED Division of Ser. No. US 1999-471179, filed on 23 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-223546, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474072, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-224246, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474071, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-223094, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-514010, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-259388, filed on 26 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-597993, filed on 19 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-336536, filed on 18 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-630334, filed on 31 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-365164, filed on 30 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-665666, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-399723, filed on 20 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-667751, filed on 21 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-409634, filed on 30 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-572002, filed on 15 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-312359, filed on 14 May 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-606565, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-342687, filed on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-606317, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-345464, filed on 30 Jun 1999, ABANDONED
PRAI US 1999-122458P 19990301 (60)
DT Utility
FS APPLICATION
LN.CNT 22222
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04

L19 ANSWER 2 OF 24 USPATFULL
AN 2003:24162 USPATFULL
TI Gene therapy of diseases associated with the immune system, using a cell-specific active compound which is regulated by the cell cycle
IN Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF

PI US 2003018005 A1 20030123
AI US 2002-112953 A1 20020402 (10)
RLI Continuation of Ser. No. US 1997-793109, filed on 25 Apr 1997, GRANTED, Pat. No. US 6384202
PRAI GB 1994-17366 19940826
GB 1995-6466 19950329
DE 1995-19524720 19950712
DT Utility
FS APPLICATION
LN.CNT 3163
INCL INCLM: 514/044.000
INCLS: 536/023.200; 536/023.500
NCL NCLM: 514/044.000
NCLS: 536/023.200; 536/023.500
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 24 USPATFULL
AN 2002:315069 USPATFULL
TI Compositions and methods for treatment of neoplastic disease
IN Terman, David S., Pebble Beach, CA, UNITED STATES
PI US 2002177551 A1 20021128
AI US 2001-870759 A1 20010530 (9)
PRAI US 2000-208128P 20000531 (60)
DT Utility
FS APPLICATION
LN.CNT 17323
INCL INCLM: 514/012.000
INCLS: 435/325.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 435/325.000; 530/350.000
IC [7]
ICM: A61K038-17
ICS: C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 24 USPATFULL
AN 2002:301110 USPATFULL
TI Hematopoietic growth factor inducible neurokinin-1 gene
IN Rameshwar, Pranela, Maplewood, NJ, UNITED STATES
PA University of Medicine & Dentistry of New Jersey (2)
PI US 2002168653 A1 20021114
AI US 2001-39272 A1 20011020 (10)
PRAI US 2000-241881P 20001020 (60)
DT Utility
FS APPLICATION
LN.CNT 3139
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 24 USPATFULL
AN 2002:213436 USPATFULL
TI Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
IN Rubinfeld, Joseph, Danville, CA, UNITED STATES
Chang, Lucy, San Mateo, CA, UNITED STATES
DiMartino, Jorge, San Carlos, CA, UNITED STATES
PI US 2002114809 A1 20020822
AI US 2001-790483 A1 20010221 (9)
DT Utility
FS APPLICATION
LN.CNT 1466
INCL INCLM: 424/155.100
INCLS: 424/277.100; 424/649.000; 514/254.070; 514/269.000; 514/283.000; 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000
NCL NCLM: 424/155.100
NCLS: 424/277.100; 424/649.000; 514/254.070; 514/269.000; 514/283.000; 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000
IC [7]
ICM: A61K039-00
ICS: A61K039-395; A61K031-57; A61K031-495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 24 USPATFULL
AN 2002:191201 USPATFULL
TI Uses of monoclonal **antibody** 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002102264 A1 20020801
AI US 2001-982645 A1 20011018 (9)
PRAI US 2000-241344P 20001018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
INCLS: 424/178.100; 530/389.100; 435/326.000
NCL NCLM: 424/155.100
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]
ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 24 USPATFULL
AN 2002:126888 USPATFULL
TI 18221, a novel dual specificity phosphatase and uses thereof
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002065406 A1 20020530
AI US 2001-815419 A1 20010322 (9)
PRAI US 2000-191858P 20000324 (60)
DT Utility
FS APPLICATION
LN.CNT 5161
INCL INCLM: 536/023.100
INCLS: 435/006.000; 435/196.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 435/196.000
IC [7]
ICM: C07H021-02
ICS: C07H021-04; C12Q001-68; C12N009-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 24 USPATFULL
AN 2002:78194 USPATFULL
TI Immunotherapy of malignant and autoimmune disorders in domestic animals using naked **antibodies**, immunoconjugates and fusion proteins
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
PI US 2002041847 A1 20020411
AI US 2001-921290 A1 20010803 (9)
RLI Continuation-in-part of Ser. No. US 1998-38995, filed on 12 Mar 1998, GRANTED, Pat. No. US 6134982 Continuation-in-part of Ser. No. US 1999-307816, filed on 10 May 1999, GRANTED, Pat. No. US 6306393
DT Utility

FS APPLICATION
LN.CNT 1783
INCL INCLM: 424/001.490
INCLS: 424/178.100; 424/154.100
NCL NCLM: 424/001.490
NCLS: 424/178.100; 424/154.100
IC [7]
ICM: A61K039-395
ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 24 USPATFULL
AN 2002:60972 USPATFULL
TI 38692 and 21117, novel dual specificity phosphatase molecules and uses therefor
IN Meyers, Rachel A., Newton, MA, UNITED STATES
PI US 2002034807 A1 20020321
AI US 2001-816494 A1 20010323 (9)
PRAI US 2000-191858P 20000324 (60)
DT Utility
FS APPLICATION
LN.CNT 5760
INCL INCLM: 435/196.000
INCLS: 435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200; 530/388.100; 514/044.000
NCL NCLM: 435/196.000
NCLS: 435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200; 530/388.100; 514/044.000
IC [7]
ICM: C12N009-16
ICS: C12Q001-68; G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 10 OF 24 USPATFULL
AN 2002:37315 USPATFULL
TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, LA, UNITED STATES
PI US 2002022031 A1 20020221
AI US 2001-924103 A1 20010808 (9)
PRAI US 2000-223698P 20000808 (60)
DT Utility
FS APPLICATION
LN.CNT 1133
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 11 OF 24 USPATFULL
AN 2002:32197 USPATFULL
TI Assay to detect a binding partner
IN Christopherson, Richard Ian, Sydney, AUSTRALIA
Dos Remedios, Cristobal Guillermo, Sydney, AUSTRALIA
PI US 2002019018 A1 20020214
AI US 2001-888959 A1 20010625 (9)
RLI Continuation of Ser. No. WO 1999-AU1156, filed on 23 Dec 1999, UNKNOWN
PRAI AU 1998-7916 19981223
AU 1999-425 19990518
DT Utility
FS APPLICATION
LN.CNT 2701
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 12 OF 24 USPATFULL
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6495129 B1 20021217
AI US 2000-689693 20001013 (9)
RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719, filed on 30 Sep 1996, now patented, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part of Ser. No. US 208339
PRAI US 2000-212658P 20000619 (60)
US 2000-211458P 20000613 (60)
US 2000-199142P 20000424 (60)
US 2000-189048P 20000314 (60)
US 1999-172063P 19991223 (60)
US 1999-164059P 19991108 (60)
US 1999-159362P 19991014 (60)
DT Utility
FS GRANTED
LN.CNT 14198
INCL INCLM: 424/085.100
INCLS: 424/885.000; 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 424/085.100
NCLS: 514/002.000; 514/008.000; 514/012.000
IC [7]
ICM: A61K038-19
EXF 424/85.1; 424/885; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 13 OF 24 USPATFULL
AN 2002:262461 USPATFULL
TI 22109, a novel human thioredoxin family member and uses thereof
IN Bandaru, Rajasekhar, Watertown, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6462187 B1 20021008
AI US 2001-882835 20010615 (9)
PRAI US 2000-211673P 20000615 (60)
DT Utility
FS GRANTED
LN.CNT 4686
INCL INCLM: 536/023.200
INCLS: 536/023.500; 435/233.000
NCL NCLM: 536/023.200

NCLS: 435/233.000; 536/023.500
IC [7]
ICM: C07H021-04
ICS: C12N009-90
EXF 435/233; 435/252.3; 435/325; 536/23.2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 14 OF 24 USPATFULL
AN 2002:174981 USPATFULL
TI 18232, a novel dual specificity phosphatase and uses therefor
IN Meyers, Rachel A., Newton, MA, United States
Weich, Nadine, Brookline, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6420153 B1 20020716
AI US 2000-704139 20001101 (9)
PRAI US 2000-185772P 20000229 (60)
DT Utility
FS GRANTED
LN.CNT 4450
INCL INCLM: 435/196.000
INCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200; 536/023.100; 536/024.100
NCL NCLM: 435/196.000
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.200; 536/024.100
IC [7]
ICM: C12N009-16
ICS: C12N001-20; C12N005-00; C07H021-02; C07H021-04
EXF 435/196; 435/252.3; 435/320.1; 435/325; 536/23.2; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 24 USPATFULL
AN 2002:102621 USPATFULL
TI Cell-specific active compounds regulated by the cell cycle
IN Sedlacek, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
PA Hoechst Aktiengesellschaft, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6384202 B1 20020507
WO 9606941 19960307
AI US 1997-793109 19970425 (8)
WO 1995-EP3371 19950825
19970425 PCT 371 date
PRAI GB 1994-17366 19940826
GB 1995-6466 19950329
DE 1995-19524720 19950712
DT Utility
FS GRANTED
LN.CNT 2654
INCL INCLM: 536/023.100
INCLS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; 536/024.100
NCL NCLM: 536/023.100
NCLS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; 536/024.100
IC [7]
ICM: A01N063-00
ICS: A61K048-00; C07H021-02; C12N015-63
EXF 536/23.5; 536/24.1; 536/23.1; 514/44; 435/320.1; 424/93.1; 424/93.2; 424/93.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 16 OF 24 USPATFULL
AN 1999:170208 USPATFULL
TI Therapeutic uses of the hypervariable region of monoclonal **antibody** M195 and constructs thereof
IN Scheinberg, David A., New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 6007814 19991228
AI US 1992-861967 19920615 (7)
RLI Continuation-in-part of Ser. No. US 450918
DT Utility
FS Granted
LN.CNT 4174
INCL INCLM: 424/130.100
INCLS: 424/133.100; 424/152.100; 424/153.100; 424/155.100; 424/173.100; 424/178.100; 424/183.100; 530/387.300; 530/387.700; 530/388.200; 530/388.700; 530/388.600; 530/388.800; 530/389.600; 530/389.700; 530/391.300; 530/391.700
NCL NCLM: 424/130.100
NCLS: 424/133.100; 424/152.100; 424/153.100; 424/155.100; 424/173.100; 424/178.100; 424/183.100; 530/387.300; 530/387.700; 530/388.200; 530/388.600; 530/388.700; 530/388.800; 530/389.600; 530/389.700; 530/391.300; 530/391.700
IC [6]
ICM: C07K016-28
ICS: C07K016-46; A61K039-395
EXF 530/387.3; 530/387.7; 530/387.73; 530/387.75; 530/388; 530/8; 530/391.7; 530/391.3; 530/388.2; 530/388.7; 530/389.6; 530/389.7; 435/240.27; 435/72.2; 435/70.21; 424/134.1; 424/138.1; 424/153.1-156.1; 424/130.1; 424/133.1; 424/152.1; 424/173.1; 424/178.1; 424/183.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 24 USPATFULL
AN 1999:27752 USPATFULL
TI Process for preparing conjugates of methyltrithio antitumor agents
IN Hamann, Philip Ross, Garnerville, NY, United States
Hinman, Lois, N. Tarrytown, NY, United States
Hollander, Irwin, Monsey, NY, United States
Holcomb, Ryan, Glen Rock, NJ, United States
Hallett, William, New City, NY, United States
Tsou, Hwei-Ru, New City, NY, United States
Weiss, Martin J., Ft. Lee, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5877296 19990302
AI US 1995-452164 19950526 (8)
RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994, now patented, Pat. No. US 5773001
DT Utility
FS Granted
LN.CNT 3894
INCL INCLM: 530/391.700
INCLS: 514/025.000; 514/026.000; 514/053.000; 514/168.000; 530/391.100; 530/391.900
NCL NCLM: 530/391.700
NCLS: 530/391.100; 530/391.900
IC [6]
ICM: C07K016-00
ICS: A01N043-04; C12P019-44
EXF 530/391.1; 530/391.7; 530/391.9; 514/25; 514/26; 514/53; 514/168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 24 USPATFULL
AN 1998:75158 USPATFULL
TI Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
IN Hamann, Philip Ross, Garnerville, NY, United States
Hinman, Lois, N. Tarrytown, NY, United States

Hollander, Irwin, Monsey, NY, United States
Holcomb, Ryan, Glen Rock, NJ, United States
Hallett, William, New City, NY, United States
Tsou, Hwei-Ru, New City, NY, United States
Weiss, Martin J., Ft. Lee, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5773001 19980630
AI US 1994-253877 19940603 (8)
DT Utility
FS Granted
LN.CNT 3777
INCL INCLM: 424/181.100
INCLS: 514/025.000; 514/053.000; 514/054.000; 514/061.000; 514/069.000; 530/391.100; 530/402.000; 536/016.800
NCL NCLM: 424/181.100
NCLS: 514/025.000; 514/053.000; 514/054.000; 514/061.000; 514/069.000; 530/391.100; 530/402.000; 536/016.800
IC [6]
ICM: A61K039-395
ICS: C07K016-00; C07G011-00
EXF 530/391.9; 530/399; 530/402; 424/181.1; 514/12; 514/25.26; 514/169.53; 514/54.61; 552/500; 435/74; 536/16.8; 536/17.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 19 OF 24 USPATFULL
AN 1998:69196 USPATFULL
TI Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents
IN Hamann, Philip Ross, Garnerville, NY, United States
Hinman, Lois, N. Tarrytown, NY, United States
Hollander, Irwin, Monsey, NY, United States
Holcomb, Ryan, Glen Rock, NJ, United States
Hallett, William, New City, NY, United States
Tsou, Hwei-Ru, New City, NY, United States
Weiss, Martin J., Ft. Lee, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5767285 19980616
AI US 1995-462939 19950605 (8)
RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994
DT Utility
FS Granted
LN.CNT 2848
INCL INCLM: 548/542.000
INCLS: 544/038.000; 560/019.000; 564/152.000; 564/163.000; 530/391.900; 530/402.000
NCL NCLM: 548/542.000
NCLS: 530/391.900; 530/402.000; 544/038.000; 560/019.000; 564/152.000; 564/163.000
IC [6]
ICM: C07D207-46
ICS: C07D207-48; C07D295-22
EXF 530/391.9; 530/399; 530/402; 514/12; 514/25; 514/26; 514/54; 514/61; 514/53; 514/169; 544/38; 548/542; 560/19; 564/152; 564/163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 24 USPATFULL
AN 1998:39508 USPATFULL
TI Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
IN Hamann, Philip Ross, Garnerville, NY, United States
Hinman, Lois, Tarrytown, NY, United States
Hollander, Irwin, Monsey, NY, United States
Holcomb, Ryan, Glen Rock, NJ, United States
Hallett, William, New City, NY, United States
Tsou, Hwei-Ru, New City, NY, United States
Weiss, Martin J., Ft. Lee, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 5739116 19980414
AI US 1995-461284 19950605 (8)
RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994
DT Utility
FS Granted
LN.CNT 2862
INCL INCLM: 514/025.000
INCLS: 514/005.000; 514/012.000; 514/053.000; 514/056.000; 514/061.000; 424/178.100; 536/016.800; 536/017.500
NCL NCLM: 514/025.000
NCLS: 424/178.100; 514/005.000; 514/012.000; 514/053.000; 514/056.000; 514/061.000; 536/016.800; 536/017.500
IC [6]
ICM: A01N043-04
ICS: A01N045-00; A61K039-00; C12P019-44
EXF 530/391.9; 530/399; 530/402; 514/12; 514/25; 514/26; 514/54; 514/61; 514/169.53; 514/5; 514/53; 424/178.1; 536/16.8; 536/17.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 21 OF 24 USPATFULL
AN 1998:30697 USPATFULL
TI Therapeutic use of hypervariable region of monoclonal **antibody** M195 and constructs thereof
IN Scheinberg, David A., New York, NY, United States
PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
PI US 5730982 19980324
AI US 1995-383615 19950202 (8)
RLI Continuation of Ser. No. US 1993-56957, filed on 3 May 1993, now abandoned which is a continuation of Ser. No. US 1989-450918, filed on 14 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 2528
INCL INCLM: 424/181.100
INCLS: 424/183.100; 530/388.220; 530/391.300; 530/391.500; 530/391.700; 530/391.900
NCL NCLM: 424/181.100
NCLS: 424/183.100; 530/388.220; 530/391.300; 530/391.500; 530/391.700; 530/391.900
IC [6]
ICM: A61K039-395
ICS: C07K016-28
EXF 530/391.3; 530/391.7; 530/387.7; 530/388.7; 530/387.3; 530/388.22; 530/391.5; 530/391.9; 435/240.27; 424/178.1; 424/183.1; 424/144.1; 424/154.1; 424/155.1; 424/181.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 22 OF 24 USPATFULL
AN 97:94073 USPATFULL
TI Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
IN Simmons, Paul J., Adelaide, Australia
Hill, Beth L., Mountain View, CA, United States
Chen, Benjamin P., Fremont, CA, United States
PA Systemix, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5677136 19971014
AI US 1994-340047 19941114 (8)
DT Utility
FS Granted
LN.CNT 1556
INCL INCLM: 435/007.240
INCLS: 435/002.000; 435/030.000; 435/240.200; 435/240.270; 530/388.700

NCL NCLM: 435/007.240
NCLS: 435/002.000; 435/030.000; 435/343.000; 435/372.000; 530/388.700
IC [6]
ICM: C07K016-28
ICS: C12N005-08; C12Q001-24
EXF 435/2; 435/7.24; 435/30; 435/240.2; 435/240.27; 530/388.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 24 USPATFULL
AN 97:44908 USPATFULL
TI WT1 monoclonal **antibodies** and methods of use therefor
IN Herlyn, Meenhard, Wynnewood, PA, United States
Morris, Jennifer, Brookfield, WI, United States
Rauscher, III, Frank J., Cranbury, NJ, United States
Rodeck, Ulrich, Philadelphia, PA, United States
PA The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United States (U.S. corporation)
PI US 5633142 19970527
AI US 1995-456907 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994
DT Utility
FS Granted
LN.CNT 1214
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700; 530/388.100; 530/388.800; 530/809.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700; 530/388.100; 530/388.800; 530/809.000
IC [6]
ICM: G01N033-547
ICS: G01N033-53; C07K016-30; C07K016-18
EXF 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1; 530/388.8; 530/809
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 24 OF 24 USPATFULL
AN 97:33630 USPATFULL
TI WT1 monoclonal **antibodies**
IN Herlyn, Meenhard, Wynnewood, PA, United States
Morris, Jennifer, Wilmington, DE, United States
Rauscher, III, Frank J., Cranbury, NJ, United States
Rodeck, Ulrich, Philadelphia, PA, United States
PA The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
PI US 5622835 19970422
AI US 1994-234783 19940428 (8)
DT Utility
FS Granted
LN.CNT 1265
INCL INCLM: 435/328.000
INCLS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850; 435/070.210; 435/172.200; 435/331.000; 435/344.000; 435/344.100
NCL NCLM: 435/328.000
NCLS: 435/070.210; 435/331.000; 435/344.000; 435/344.100; 435/975.000; 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850
IC [6]
ICM: C12N005-12
ICS: C07K016-00; C07K016-18; C07K016-30
EXF 435/240.27; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9; 530/388.1; 530/388.85; 530/388.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
ENTERED AT 14:14:19 ON 12 FEB 2003
L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA
L12 32001 S CML
L13 3824 S L12 AND GRANULOCYTE
L14 831 S L13 AND ANTIBOD?
L15 23 S L14 AND NCA?
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)
L17 204 S L14 AND HUMANIZ?
L18 24 S L17 AND CD33
L19 24 DUP REM L18 (0 DUPLICATES REMOVED)

=> s l14 and treat?
L20 537 L14 AND TREAT?

=> s l20 and mn3
L21 0 L20 AND MN3

=> s l20 and mn2
L22 1 L20 AND MN2

=> d l ab

L22 ANSWER 1 OF 1 USPATFULL
AB The invention provides isolated nucleic acids molecules, designated 56294 and 56229 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56294 or 56629nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56294 or 56629 gene has been introduced or disrupted. The invention still further provides isolated 56294 or 56629 proteins, fusion proteins, antigenic peptides and anti-56294, anti-56629 **antibodies**. Diagnostic methods utilizing compositions of the invention are also provided.

=> d l ibib

L22 ANSWER 1 OF 1 USPATFULL
ACCESSION NUMBER: 2003:23732 USPATFULL
TITLE: 56294 and 56629, novel human metalloproteases and uses thereof
INVENTOR(S): Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003017572	A1	20030123
APPLICATION INFO.:	US 2001-961656	A1	20010924 (9)

	NUMBER	DATE

PRIORITY INFORMATION: US 2000-235035P 20000925 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 5895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003

L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA
L12 32001 S CML
L13 3824 S L12 AND GRANULOCYTE
L14 831 S L13 AND ANTIBOD?
L15 23 S L14 AND NCA?
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)
L17 204 S L14 AND HUMANIZ?
L18 24 S L17 AND CD33
L19 24 DUP REM L18 (0 DUPLICATES REMOVED)
L20 537 S L14 AND TREAT?
L21 0 S L20 AND MN3
L22 1 S L20 AND MN2

=> s l20 and cea
L23 13 L20 AND CEA

=> dup rem l23
PROCESSING COMPLETED FOR L23
L24 13 DUP REM L23 (0 DUPLICATES REMOVED)

=> d 1-13

L24 ANSWER 1 OF 13 USPATFULL
AN 2003:23733 USPATFULL
TI Polymerase kappa compositions and methods thereof
IN Friedberg, Errol C., Dallas, TX, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Feaver, William J., Branford, CT, UNITED STATES
PA Board of Regents, The University of Texas system (U.S. corporation)
PI US 2003017573 A1 20030123
AI US 2001-971101 A1 20011004 (9)
PRAI US 2000-238289P 20001004 (60)
DT Utility
FS APPLICATION
LN.CNT 7042
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06

L24 ANSWER 2 OF 13 USPATFULL
AN 2002:191201 USPATFULL
TI Uses of monoclonal **antibody** 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002102264 A1 20020801
AI US 2001-982645 A1 20011018 (9)
PRAI US 2000-241344P 20001018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
INCLS: 424/178.100; 530/389.100; 435/326.000
NCL NCLM: 424/155.100
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]
ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 13 USPATFULL
AN 2002:37315 USPATFULL
TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, LA, UNITED STATES
PI US 2002022031 A1 20020221
AI US 2001-924103 A1 20010808 (9)
PRAI US 2000-223698P 20000808 (60)
DT Utility
FS APPLICATION
LN.CNT 1133
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 4 OF 13 USPATFULL
AN 2002:22535 USPATFULL
TI PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR **TREATING** CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL
IN WARRELL, RAYMOND P., JR., WESTFIELD, NJ, UNITED STATES
PANDOLFI, PIER PAOLO, NEW YORK, NY, UNITED STATES
GABRILOVE, JANICE L., NEW YORK, NY, UNITED STATES
PI US 2002013371 A1 20020131
AI US 1998-189965 A1 19981110 (9)
PRAI US 1997-64655P 19971110 (60)
DT Utility
FS APPLICATION
LN.CNT 1391
INCL INCLM: 514/623.000
NCL NCLM: 514/623.000
IC [7]
ICM: A61K031-47
ICS: A61K031-165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 5 OF 13 USPATFULL
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid

progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6495129 B1 20021217
AI US 2000-689693 20001013 (9)
RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719, filed on 30 Sep 1996, now patented, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part of Ser. No. US 208339
PRAI US 2000-212658P 20000619 (60)
US 2000-211458P 20000613 (60)
US 2000-199142P 20000424 (60)
US 2000-189048P 20000314 (60)
US 1999-172063P 19991223 (60)
US 1999-164059P 19991108 (60)
US 1999-159362P 19991014 (60)
DT Utility
FS GRANTED
LN.CNT 14198
INCL INCLM: 424/085.100
INCLS: 424/885.000; 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 424/085.100
NCLS: 514/002.000; 514/008.000; 514/012.000
IC [7]
ICM: A61K038-19
EXF 424/85.1; 424/885; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 6 OF 13 USPATFULL
AN 2002:297455 USPATFULL
TI Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
IN Nelson, Edward L., Eldersburg, MD, United States
Strobl, Susan L, Hagerstown, MD, United States
PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6479286 B1 20021112
WO 9853048 19991126
AI US 2000-424173 20000605 (9)
WO 1999-US9810311 19990520
20000605 PCT 371 date
PRAI US 1997-47348P 19970521 (60)
DT Utility
FS GRANTED
LN.CNT 2385
INCL INCLM: 435/377.000
INCLS: 435/325.000; 435/375.000; 435/455.000; 424/093.100; 424/093.400; 424/093.710
NCL NCLM: 435/377.000
NCLS: 424/093.100; 424/093.400; 424/093.710; 435/325.000; 435/375.000; 435/455.000
IC [7]
ICM: C12N005-00
ICS: C12N015-63; A61K035-00
EXF 435/325; 435/375; 435/377; 435/455; 514/44; 424/93.21; 424/93.71
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 7 OF 13 USPATFULL
AN 2002:230597 USPATFULL
TI Non-myeloablative tolerogenic **treatment**
IN Slavin, Shimon, Jerusalem, ISRAEL
Prigozhina, Tatyana, Rehovot, ISRAEL
PA Hadasit Medical Research Services and Development Ltd., Jerusalem, ISRAEL (non-U.S. corporation)
PI US 6447767 B1 20020910
AI US 2000-506082 20000216 (9)
RLI Continuation-in-part of Ser. No. US 1998-222011, filed on 31 Dec 1998 Continuation-in-part of Ser. No. US 1997-862550, filed on 23 May 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 3356
INCL INCLM: 424/093.100
INCLS: 424/093.210; 514/002.000; 514/044.000; 435/325.000
NCL NCLM: 424/093.100
NCLS: 424/093.210; 435/325.000; 514/002.000; 514/044.000
IC [7]
ICM: A61K038-00
ICS: A61K048-00; C12N015-85
EXF 424/93.21; 424/93.1; 514/2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 8 OF 13 USPATFULL
AN 2001:170889 USPATFULL
TI Monocyte-derived dendritic cell subsets
IN Punnonen, Juha, Palo Alto, CA, United States
Chang, Chia-Chun J., Los Gatos, CA, United States
PI US 2001026937 A1 20011004
AI US 2001-760388 A1 20010110 (9)
PRAI US 2000-175552P 20000111 (60)
US 2000-181957P 20000210 (60)
DT Utility
FS APPLICATION
LN.CNT 3189
INCL INCLM: 435/366.000
INCLS: 435/325.000; 435/373.000; 424/093.210
NCL NCLM: 435/366.000
NCLS: 435/325.000; 435/373.000; 424/093.210
IC [7]
ICM: A61K048-00
ICS: A01N063-00; C12N005-00; C12N005-02

L24 ANSWER 9 OF 13 USPATFULL
AN 2001:119059 USPATFULL
TI Immunomodulating compositions for **treatment** of immune system disorders
IN Rang, Romeo G., Bucharest, Romania
Percheson, Paul B., Ontario, Canada
PI US 2001009680 A1 20010726
AI US 2001-764010 A1 20010117 (9)
RLI Continuation of Ser. No. US 1995-404932, filed on 16 Mar 1995, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3900
INCL INCLM: 424/528.000

NCL NCLM: 424/528.000
IC [7]
ICM: A61K035-413

L24 ANSWER 10 OF 13 USPATFULL
AN 2000:149714 USPATFULL
TI Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
IN Slavin, Shimon, Jerusalem, Israel
PA Baxter International Inc., Deerfield, IL, United States (U.S. corporation)
Hadasit Medical Research Services and Development Ltd., Jerusalem, Israel (non-U.S. corporation)
PI US 6143292 20001107
WO 9637208 19961128
AI US 1997-930071 19971121 (8)
WO 1996-US7652 19960524
19971121 PCT 371 date
19971121 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-449764, filed on 25 May 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1347
INCL INCLM: 424/093.700
INCLS: 424/093.710; 424/085.500; 424/085.700; 424/085.200; 424/085.400; 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000
NCL NCLM: 424/093.700
NCLS: 424/085.200; 424/085.400; 424/085.500; 424/085.700; 424/093.710; 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000
IC [7]
ICM: A61K035-28
ICS: C12N005-08
EXF 424/93.71; 424/93.7; 424/85.5; 424/85.7; 424/85.2; 424/85.4; 424/144.1; 424/577; 424/578; 435/325; 435/372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 11 OF 13 USPATFULL
AN 97:44908 USPATFULL
TI WT1 monoclonal **antibodies** and methods of use therefor
IN Herlyn, Meenhard, Wynnewood, PA, United States
Morris, Jennifer, Brookfield, WI, United States
Rauscher, III, Frank J., Cranbury, NJ, United States
Rodeck, Ulrich, Philadelphia, PA, United States
PA The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United States (U.S. corporation)
PI US 5633142 19970527
AI US 1995-456907 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994
DT Utility
FS Granted
LN.CNT 1214
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700; 530/388.100; 530/388.800; 530/809.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700; 530/388.100; 530/388.800; 530/809.000
IC [6]
ICM: G01N033-547
ICS: G01N033-53; C07K016-30; C07K016-18
EXF 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1; 530/388.8; 530/809
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 12 OF 13 USPATFULL
AN 97:33630 USPATFULL
TI WT1 monoclonal **antibodies**
IN Herlyn, Meenhard, Wynnewood, PA, United States
Morris, Jennifer, Wilmington, DE, United States
Rauscher, III, Frank J., Cranbury, NJ, United States
Rodeck, Ulrich, Philadelphia, PA, United States
PA The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
PI US 5622835 19970422
AI US 1994-234783 19940428 (8)
DT Utility
FS Granted
LN.CNT 1265
INCL INCLM: 435/328.000
INCLS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850; 435/070.210; 435/172.200; 435/331.000; 435/344.000; 435/344.100
NCL NCLM: 435/328.000
NCLS: 435/070.210; 435/331.000; 435/344.000; 435/344.100; 435/975.000; 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850
IC [6]
ICM: C12N005-12
ICS: C07K016-00; C07K016-18; C07K016-30
EXF 435/240.27; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9; 530/388.1; 530/388.85; 530/388.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 13 OF 13 USPATFULL
AN 90:57750 USPATFULL
TI Lateral flow, non-bibulous membrane assay protocols
IN Eisinger, Robert W., San Diego, CA, United States
Khalil, Mohammed H., San Diego, CA, United States
Katz, David H., La Jolla, CA, United States
Sargeant, Robert B., Ramona, CA, United States
PA Quidel, San Diego, CA, United States (U.S. corporation)
PI US 4943522 19900724
AI US 1988-230642 19880810 (7)
RLI Continuation-in-part of Ser. No. US 1987-57273, filed on 1 Jun 1987, now abandoned And a continuation-in-part of Ser. No. US 1987-57271, filed on 1 Jun 1987, now abandoned
DT Utility
FS Granted
LN.CNT 1768
INCL INCLM: 435/007.000
INCLS: 435/805.000; 435/810.000; 436/512.000; 436/514.000; 436/518.000; 436/520.000; 436/523.000; 436/531.000; 436/535.000; 436/807.000; 436/808.000; 436/810.000; 422/055.000; 422/056.000; 422/057.000; 422/058.000; 422/101.000
NCL NCLM: 435/007.250
NCLS: 422/055.000; 422/056.000; 422/057.000; 422/058.000; 422/101.000; 435/005.000; 435/007.210; 435/007.230; 435/007.320; 435/805.000; 435/810.000; 436/512.000; 436/514.000; 436/518.000; 436/520.000; 436/523.000; 436/531.000; 436/535.000; 436/807.000; 436/808.000; 436/810.000; D24/223.000
IC [5]
ICM: G01N033-53
EXF 422/55-61; 422/70; 422/101; 422/102; 424/11; 435/7; 435/5; 435/805; 435/810; 436/514-520; 436/512; 436/523; 436/531; 436/535; 436/807; 436/808; 436/810; 210/431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	190.99	191.20

STN INTERNATIONAL LOGOFF AT 14:48:34 ON 12 FEB 2003

=> d 17 18 ibib ab

L16 ANSWER 17 OF 18 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 91187141 MEDLINE
DOCUMENT NUMBER: 91187141 PubMed ID: 2011210
TITLE: Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
AUTHOR: Noworolska A; Slesak B; Harlonzinska A; Richter R
CORPORATE SOURCE: Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
SOURCE: NEOPLASMA, (1991) 38 (1) 57-62.
Journal code: 0377266. ISSN: 0028-2685.
PUB. COUNTRY: Czech Republic
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 19910526
Last Updated on STN: 19960719
Entered Medline: 19910503

AB The distribution of peanut agglutinin (PNA) receptors, nonspecific cross-reacting antigen (**NCA**) molecule and 3-fucosyl-N-acetyllactosamine (FAL) in myeloid leukemic cells isolated by density gradient centrifugation was compared using immunofluorescence test (IF). Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low percentage of **NCA**+ and PNA+ cells. In chronic and acute phase of chronic myelocytic leukemias (**CML**) the number of **NCA** containing cells increased and the amount of PNA-binding cells decreased as more mature granulocytic fractions were isolated on Ficoll--Uropoline density gradient. In patients with myeloblastic crisis of **CML** (**CML**-BC) the number of cells expressing FAL structure did not change in relation to maturation stage of myeloid cells. Our results revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature **granulocytes**.

L16 ANSWER 18 OF 18 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 82141196 MEDLINE
DOCUMENT NUMBER: 82141196 PubMed ID: 6949877
TITLE: Clinical evaluation of **NCA** in patients with chronic myelocytic leukemia.
AUTHOR: Wahren B; Gahrton G; Ruden U; Hammarstrom S
SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7.
Journal code: 0042124. ISSN: 0020-7136.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198205
ENTRY DATE: Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820512

AB **NCA**, a normal colon and **granulocyte** antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil **granulocytes**, was studied in 50 **CML** patients in various stages of the disease. Radioimmunoassay was used to demonstrate **NCA** in serum. Untreated **CML** patients had a mean level of 732 micrograms **NCA**/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms **NCA**/l. The serum **NCA** levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of **CML**. In blast crisis low

values with a mean of 109 micrograms **NCA**/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of **NCA** could not be attributed to **antibodies** to **NCA**.
NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of **NCA** by leukemic maturing myeloid cells.

L21 ANSWER 1 OF 1 MEDLINE
AN 92293167 MEDLINE
DN 92293167 PubMed ID: 1603094
TI Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation.
AU Grebenau R C; Goldenberg D M; Chang C H; Koch G A; Gold D V; Kunz A; **Hansen H J**
CS Immunomedics Inc., Newark, NJ 07103.
NC CA 39841 (NCI)
SO MOLECULAR IMMUNOLOGY, (1992 Jun) 29 (6) 751-8.
Journal code: 7905289. ISSN: 0161-5890.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199207
ED Entered STN: 19920724
Last Updated on STN: 19920724
Entered Medline: 19920713

=> d l21 ab

L21 ANSWER 1 OF 1 MEDLINE
AB A murine monoclonal anti-granulocyte IgG1, IMMU-**MN3**, was seen to exhibit heterogeneity. On reduced SDS-PAGE, the purified antibody appeared as two heavy-chain bands of unequal intensity, and only one light-chain band. Hydrophobic interaction chromatography (HIC) also resolved two populations of the IMMU-**MN3** antibody. Based on Concanavalin A affinity chromatography, enzymatic digestion with Endoglycosidase F and carbohydrate analysis, it was found that the heterogeneity detected by SDS-PAGE and HIC was due to differences in glycosylation. Furthermore, sequential gel analysis (non-reduced/reduced) demonstrated that the upper heavy-chain band was asymmetrically glycosylated.

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 89000602 EMBASE
DOCUMENT NUMBER: 1989000602
TITLE: In vivo labelling of granulocytes using 123I-tagged anti-**granulocyte antibodies**.
AUTHOR: Seybold K.
CORPORATE SOURCE: Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland
SOURCE: Nuclear Medicine Communications, (1988) 9/10 (745-752).
ISSN: 0143-3636 CODEN: NMCODC
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT: 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; **NCA** 95) of normal human granulocytes. This new tracer was quality tested and radioiodinated with 123I (123I Mab 47) for clinical use according to established procedures. Extended in vitro studies revealed a high selectivity for granulocytes without inhibiting their vital functions. In vivo cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of 123I. Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of 123I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of 111In-labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.